<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005493.pub2" GROUP_ID="INCONT" ID="739405082308554739" MERGED_FROM="" MODIFIED="2011-11-09 19:12:10 +0100" MODIFIED_BY="Muhammad Imran Omar" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2011-11-09 18:09:54 +0000" NOTES_MODIFIED_BY="Muhammad Imran Omar" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.1.2" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.10">
<COVER_SHEET MODIFIED="2011-11-09 19:12:10 +0100" MODIFIED_BY="Muhammad Imran Omar">
<TITLE>Botulinum toxin injections for adults with overactive bladder syndrome</TITLE>
<CONTACT MODIFIED="2011-11-09 19:12:10 +0100" MODIFIED_BY="Muhammad Imran Omar"><PERSON ID="E8F6717082E26AA200334BFE9A0A0C92" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>James</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Duthie</LAST_NAME><POSITION>Urology Registrar</POSITION><EMAIL_1>jbduthie@gmail.com</EMAIL_1><ADDRESS><ORGANISATION>Wellington Hospital</ORGANISATION><ADDRESS_1>Riddiford Street</ADDRESS_1><CITY>Newtown</CITY><ZIP>6021</ZIP><REGION>Wellington</REGION><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 34530072</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-11-09 19:12:10 +0100" MODIFIED_BY="Muhammad Imran Omar"><PERSON ID="E8F6717082E26AA200334BFE9A0A0C92" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>James</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Duthie</LAST_NAME><POSITION>Urology Registrar</POSITION><EMAIL_1>jbduthie@gmail.com</EMAIL_1><ADDRESS><ORGANISATION>Wellington Hospital</ORGANISATION><ADDRESS_1>Riddiford Street</ADDRESS_1><CITY>Newtown</CITY><ZIP>6021</ZIP><REGION>Wellington</REGION><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 34530072</PHONE_1></ADDRESS></PERSON><PERSON ID="34337322267676500164100210124927" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Michael</FIRST_NAME><LAST_NAME>Vincent</LAST_NAME><POSITION>Urology Registrar</POSITION><EMAIL_1>mwvincent@doctors.org.uk</EMAIL_1><ADDRESS><ORGANISATION>Kew Hospital</ORGANISATION><CITY>Invercargill</CITY><COUNTRY CODE="NZ">New Zealand</COUNTRY></ADDRESS></PERSON><PERSON ID="4695" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>G Peter</FIRST_NAME><LAST_NAME>Herbison</LAST_NAME><POSITION>Statistician</POSITION><EMAIL_1>peter.herbison@otago.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>Department of Preventive &amp; Social Medicine</DEPARTMENT><ORGANISATION>Dunedin School of Medicine, University of Otago</ORGANISATION><ADDRESS_2>PO Box 913</ADDRESS_2><CITY>Dunedin</CITY><ZIP>9054</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 3 4797217</PHONE_1><FAX_1>+64 3 4797298</FAX_1></ADDRESS></PERSON><PERSON ID="96A4129B82E26AA201650CEA5BD27232" ROLE="AUTHOR"><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>Iain</MIDDLE_INITIALS><LAST_NAME>Wilson</LAST_NAME><EMAIL_1>d_i_wilson@yahoo.co.uk</EMAIL_1><ADDRESS><DEPARTMENT>Emergency Department</DEPARTMENT><ORGANISATION>Queen's Hospital</ORGANISATION><ADDRESS_1>Romford</ADDRESS_1><CITY>Essex</CITY><ZIP>RM7 0AG</ZIP><COUNTRY CODE="GB">UK</COUNTRY><FAX_1>+44 207 2885038</FAX_1></ADDRESS></PERSON><PERSON ID="5097" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Don</FIRST_NAME><LAST_NAME>Wilson</LAST_NAME><POSITION>Consultant and Head of Discipline</POSITION><EMAIL_1>don.wilson@otago.ac.nz</EMAIL_1><ADDRESS><DEPARTMENT>Women's and Children's Health</DEPARTMENT><ORGANISATION>Dunedin School of Medicine, University of Otago</ORGANISATION><ADDRESS_1>PO Box 913</ADDRESS_1><CITY>Dunedin</CITY><ZIP>9054</ZIP><COUNTRY CODE="NZ">New Zealand</COUNTRY><PHONE_1>+64 3 474 7951 ext 8567</PHONE_1><FAX_1>+64 3 474 7620</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-11-08 14:18:32 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="23" MONTH="2" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="2" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="8" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2011-11-09 15:58:33 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2011-11-08 15:07:47 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="29" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>Updated review with 11 additional studies</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-11-09 15:58:33 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="30" MONTH="3" YEAR="2011"/>
<DESCRIPTION>
<P>new search 23 Feb 2010</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="22" MONTH="5" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-11-09 17:31:21 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-11-09 15:18:05 +0000" MODIFIED_BY="[Empty name]">
<TITLE>Botulinum toxin injections into the bladder for overactive bladder syndrome in adults</TITLE>
<SUMMARY_BODY MODIFIED="2011-11-09 15:18:05 +0000" MODIFIED_BY="[Empty name]">
<P>Injection of botulinum toxin into the bladder is being increasingly used to treat persistent overactive bladder (OAB). This is a disorder characterised by the sudden urge to pass urine with or without incontinence, a frequent need to pass urine, and waking to pass urine during the night. We explored the research relating to how effective and safe botulinum toxin injections into the bladder are, and what the best dose of botulinum toxin is, and what is the best way of injecting it into the bladder. We found that there were several comparative studies, but these involved a relatively small number of patients. There was evidence that botulinum toxin improves the symptoms of OAB. It was unclear what the best dose of botulinum toxin was. Botulinum toxin injections into the bladder appeared to give few side effects or complications, but there were no long-term follow-up studies, and there could be rare side effects that have not been discovered yet.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-11-09 15:19:25 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-11-09 15:06:19 +0000" MODIFIED_BY="[Empty name]">
<P>Overactive bladder syndrome (OAB) is a common condition with a significant negative impact on quality of life characterised by urgency with or without urge incontinence, frequency and nocturia.  Intravesical botulinum toxin is being increasingly used to treat severe overactive bladder refractory to standard management.  An increasing body of literature is forming that supports this technique as effective, well tolerated, and safe.  This review is a substantial update of the 2007 review of the same title.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-11-09 15:18:36 +0000" MODIFIED_BY="[Empty name]">
<P>The objective was to compare intravesical botulinum toxin with other treatments for neurogenic and idiopathic overactive bladder in adults. The hypothesis to be addressed were whether intravesical injection of botulinum toxin was better than placebo or no treatment; pharmacological and other non-pharmacological interventions; whether higher doses of botulinum toxin were better than lower doses; whether botulinum toxin in combination with other treatments was better than other treatments alone; whether one formulation of botulinum toxin is better than another; and whether one injection technique was better than another.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-12-06 07:17:46 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Incontinence Group Specialised Trials Register (searched 23 February 2010). The Register contains trials identified from MEDLINE, CINAHL, the Cochrane Central Register of Controlled Trials (CENTRAL), and handsearching of journals and conference proceedings. Additionally, all reference lists of selected trials and relevant review papers were searched. No limitations were placed on the searches.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-11-09 15:18:58 +0000" MODIFIED_BY="[Empty name]">
<P>All randomised or quasi-randomised controlled trials of treatment for OAB in adults in which at least one management arm involved intravesical injection of botulinum toxin were included. Participants had either neurogenic OAB or idiopathic OAB with or without stress incontinence. Comparison interventions could include no intervention, placebo, lifestyle modification, bladder retraining, pharmacological treatments, surgery, bladder instillation techniques, neuromodulation, and different types, doses, and injection techniques of botulinum toxin.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-11-09 15:09:32 +0000" MODIFIED_BY="[Empty name]">
<P>Binary outcomes were presented as relative risk and continuous outcomes by mean differences. Little data could be synthesised across studies due to differing study designs and outcome measures. Where applicable standard deviations were calculated from P values according to the formula described in section 7.7.3.3 of the Cochrane Handbook of Systematic Reviews of Interventions. Data were tabulated where possible with results taken from trial reports where this was not possible. Where multiple publications were found, the reports were treated as a single source of data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-11-09 15:19:25 +0000" MODIFIED_BY="[Empty name]">
<P>Nineteen studies were identified that met the inclusion criteria.  Most patients in the studies had neurogenic OAB, but some included patients with idiopathic OAB.  All studies demonstrated superiority of botulinum toxin to placebo.  Lower doses of botulinum toxin (100 to 150 U) appeared to have beneficial effects, but larger doses (300 U) may have been more effective and longer lasting, but with more side effects.  Suburothelial injection had comparable efficacy to intradetrusor injection. The effect of botulinum toxin may last for a number of months and is dependent upon dose and type of toxin used. Patients receiving repeated doses do not seem to become refractory to botulinum toxin. Botulinum toxin appeared to have beneficial effects in OAB that quantitatively exceeded the effects of intravesical resiniferatoxin. Intravesical botulinum toxin appeared to be reasonably safe; however, one study was halted due to a perceived unacceptable rate of urinary retention. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-11-09 15:08:59 +0000" MODIFIED_BY="[Empty name]">
<P>Intravesical botulinum toxin appears to be an effective therapy for refractory OAB symptoms, but as yet little controlled trial data exist on benefits and safety compared with other interventions, or with placebo. Further robust data are required on long term outcomes, safety, and optimal dose of botulinum toxin for OAB.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-11-09 17:31:21 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-11-09 17:20:23 +0000" MODIFIED_BY="[Empty name]">
<P>Overactive bladder syndrome (OAB) is a symptom complex that is comprised of urinary urgency with or without urge incontinence, urinary frequency, and nocturia.  Urgency is the sudden onset of the desire to pass urine that is difficult to hold. Frequency refers to the passage of urine that is more often than is considered normal, usually more than eight times a day. The symptoms must be in the absence of any other underlying pathology including urinary tract infection <LINK REF="REF-ICS-2005" TYPE="REFERENCE">ICS 2005</LINK>.</P>
<P>OAB is estimated to affect approximately 10.9% of men and 12.9% women, with up to 28% of these men and 48% of these women reporting symptoms of incontinence <LINK REF="REF-Irwin-2006" TYPE="REFERENCE">Irwin 2006</LINK>.  The prevalence of OAB increases with age. The symptoms of OAB have been shown to significantly decrease health related quality of life and lead to increased levels of depression and anxiety <LINK REF="REF-Coyne-2009" TYPE="REFERENCE">Coyne 2009</LINK>. As well as the impact on the patient&#8217;s life, OAB has a significant financial burden associated with it <LINK REF="REF-Irwin-2008" TYPE="REFERENCE">Irwin 2008</LINK>.</P>
<P>OAB is often divided into two types: neurogenic, where the symptoms are secondary to an underlying neurological condition such as spinal cord lesions, multiple sclerosis or Parkinson&#8217;s disease; and Idiopathic, where there is no discernable pathology underlying the symptoms.  The aetiology of OAB is complex and poorly understood, but it is known that several afferent and efferent pathways as well as a multitude of neurotransmitters are involved.  Recent investigation has identified the urothelium/suburothelium as an important component in the sensory function of the bladder with several abnormalities in its expression of receptors found in patients with OAB.</P>
<P>There are a number of treatment options for OAB. The first line treatment consists of behavioural and lifestyle modifications. Treatment may be supplemented with antimuscarinic drugs, and in some cases clean intermittent catheterization (CIC).  Anti-muscarinics can improve symptoms but are often poorly tolerated, and often cause patients to discontinue treatment.  More invasive treatment options used as second or third line treatments include pudendal or sacral nerve stimulation, augmentation cystoplasty, bladder instillation of vanilloids (resiniferatoxin), and intravesical injection of botulinum toxin.  Cochrane reviews are available for many of these treatments (<LINK REF="REF-Alhasso-2009" TYPE="REFERENCE">Alhasso 2009</LINK>; <LINK REF="REF-Eustice-2000" TYPE="REFERENCE">Eustice 2000</LINK>; <LINK REF="REF-Hay_x002d_Smith-2009" TYPE="REFERENCE">Hay-Smith 2009</LINK>; <LINK REF="REF-Herbison-2009" TYPE="REFERENCE">Herbison 2009</LINK>; <LINK REF="REF-Nabi-2006" TYPE="REFERENCE">Nabi 2006</LINK>; <LINK REF="REF-Ostaszkiewicz-2004a" TYPE="REFERENCE">Ostaszkiewicz 2004a</LINK>; <LINK REF="REF-Ostaszkiewicz-2004b" TYPE="REFERENCE">Ostaszkiewicz 2004b</LINK>; <LINK REF="REF-Roxburgh-2009" TYPE="REFERENCE">Roxburgh 2009</LINK>; <LINK REF="REF-Wallace-2004" TYPE="REFERENCE">Wallace 2004</LINK>)<B>.</B>
</P>
<P>Botulinum toxin is a potent neurotoxin derived from the anaerobic bacterium Clostridium Botulinum.  There are many subtypes of the toxin but types A and B are the ones in clinical use.  Botulinum toxin is an established treatment used in cosmetic medicine, for example relaxing facial wrinkle lines, and as muscle paralytic agents for conditions such as torticollis.  Botulinum toxin is postulated to work in OAB via several separate mechanisms but its exact action is not completely understood.  It is thought to inhibit release of acetylcholine (ACh), Adenosine triphosphate (ATP) and substance P from the urothelium which have been implicated in mediating the intrinsic and spinal reflexes that lead to OAB.  Botulinum toxin also is known to inhibit release of ACh from parasympathetic nerve endings, this leads to detrusor paralysis and consequently may reduce many of the symptoms of OAB.  There is also an additional action on C-fibre afferents that is thought to be the mechanism behind the reduction in the sensation of urgency.  Research is ongoing to define the action of botulinum toxin in more detail, with several other potential mechanisms of action being studied <LINK REF="REF-Apostolidis-2006" TYPE="REFERENCE">Apostolidis 2006</LINK>; <LINK REF="REF-Cruz-2004" TYPE="REFERENCE">Cruz 2004</LINK>; <LINK REF="REF-Drake-2008" TYPE="REFERENCE">Drake 2008</LINK>.</P>
<P>Botulinum toxin is injected into several sites in the bladder wall via cystoscopy (flexible or rigid) often in a day case/outpatient setting. Either general or local anaesthesia can be used. A special injection needle is inserted via the cystoscope an the botulinum toxin is then injected into the detrusor at multiple sites, usually avoiding the trigone with several variations of technique being evaluated in different centres.  While botulinum toxin type A is the most common subtype used, botulinum toxin type B is also effective in symptom reduction, but seems to be effective for a shorter period of time.</P>
<P>Botulinum toxin has been used in the treatment of lower urinary tract disorders for many years, and although it remains unlicensed for most of these conditions a growing body of evidence is available showing its effectiveness.  There are still many questions surrounding its use, and the purpose of this review was to evaluate the current literature regarding its safety, optimal dose, injection technique and efficacy. This review is a substantial update of the 2007 review.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-11-09 17:20:32 +0000" MODIFIED_BY="[Empty name]">
<P>To compare intravesical botulinum toxin injection with other treatments for neurogenic and idiopathic OAB in adults with or without incontinence. The outcomes identified are primarily related to subjective improvements in symptoms and the duration of improvement, as OAB is principally a disease of symptoms. These symptoms were assessed using voiding diaries as well as quality of life scores. Urodynamic measures are included as outcome measures as they are often used as markers of disease. Specifically, neurogenic OAB may be associated with high intradetrusor pressures, which may cause upper renal tract complications when sustained above 40 cm H<SUB>2</SUB>0.</P>
<P>The following hypotheses were to be addressed.<BR/>1. Intravesical injection of botulinum toxin is better than placebo or no treatment.<BR/>2. Intravesical injection of botulinum toxin is better than pharmacological interventions.<BR/>3. Intravesical injection of botulinum toxin is better than other non-pharmacological interventions.<BR/>4. Higher doses of intravesical botulinum toxin are better than lower doses.<BR/>5. Intravesical injection of botulinum toxin combined with other treatments is better than other treatments alone.<BR/>6. One formulation of botulinum toxin is better than another.<BR/>7. One intravesical injection technique is better than another.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-11-09 17:20:46 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-11-09 17:20:43 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-09-02 09:21:15 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised or quasi-randomised controlled trials including crossover studies.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-11-09 17:10:11 +0000" MODIFIED_BY="[Empty name]">
<P>Adult men and women diagnosed with idiopathic or neurogenic OAB syndrome regardless of whether they also had stress incontinence.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-11-09 17:20:40 +0000" MODIFIED_BY="[Empty name]">
<P>Intravesical botulinum toxin compared against: no intervention; placebo; lifestyle modification; bladder retraining; pharmacological treatments; surgery; bladder instillation techniques; neuromodulation; and different types, doses, and injection techniques of botulinum toxin.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-11-09 17:20:43 +0000" MODIFIED_BY="[Empty name]">
<P>A. Participant's observations, for example, rating scales for improvement, perception of improvement or cure, or satisfaction with treatment.</P>
<P>B. Quantification of symptoms, for example, number of leakage episodes, frequency and volume of voids.</P>
<P>C. Clinicians' measures, for example, urodynamic measures, and clinicians' findings.</P>
<P>D. Health status and quality of life using both general (for example SF36) and condition - specific measures (for example, Incontinence Impact Questionnaire) measures and psychosocial measures.</P>
<P>E. Adverse events and issues with the use of botulinum toxin.</P>
<P>F. Socioeconomic measures -costs of interventions (for patients and providers, both direct and indirect), formal economic analysis (for example cost effectiveness), desire or need for further treatment.</P>
<P>G. Other outcomes not pre-stated but deemed important during review, for example, long-term follow up.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-11-04 10:37:11 +0000" MODIFIED_BY="[Empty name]">
<P>We did not impose any language or other limits on any of the searches.</P>
<ELECTRONIC_SEARCHES MODIFIED="2011-11-04 10:37:11 +0000" MODIFIED_BY="[Empty name]">
<P>This review has drawn on the search strategy developed for the Incontinence Review Group. Relevant trials were identified from the group's Specialised Register of Controlled Trials which is described, along with the search strategy, under the Incontinence Group's details in <I>The Cochrane Library (</I>
<A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/INCONT/frame.html">For more details please see the &#8216;Specialized Register&#8217; section of the Group&#8217;s module in The Cochrane Library</A>). The register contains trials identified from MEDLINE, CINAHL, the Cochrane Central Register of Controlled Trials (CENTRAL), and handsearching of journals and conference proceedings. The Incontinence Group's Trials Register was searched using the group's own keyword system. The search terms used were:</P>
<P>(topic.urine.incon*)<BR/>AND<BR/>({design.cct*} OR {design.rct*})<BR/>AND<BR/>({intvent.chem.botulinum*}<BR/>(All searches were of the keyword field of Reference Manager 12, Thomson Reuters).</P>
<P>Date of the most recent search of the register for this review: 23 February 2010.</P>
<P>The trials in the Incontinence Group's Specialised Register are also contained in CENTRAL.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2011-10-29 14:44:00 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the reference lists of identified articles for other possible relevant trials as well as reference lists from review articles on the topic.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-11-09 17:20:46 +0000" MODIFIED_BY="[Empty name]">
<P>Identified trials were selected for inclusion in the review on the basis of appropriateness as determined by at least two of the review authors without prior consideration of the results. No publications were in languages other than English. The review authors independently assessed the risk of bias of the trials using the Cochrane Collaboration Risk of Bias tool. This tool incorporates assessment of randomisation (sequence generation and allocation concealment), blinding (trial participants and personnel, and outcome assessors separately), completeness of outcome data, selection of outcomes reported and other sources of bias. Other sources of bias included selection bias, where we assessed the risk of bias from imbalances in key baseline characteristics. Any disagreements were decided in discussion with a third person.</P>
<P>Binary outcomes were presented as risk ratios, and continuous outcomes by mean differences. If different tools were used to measure outcomes such as quality of life, standardised mean differences were considered. Pooling of data was to be done using a fixed-effects model in the first instance. Little pooling was possible because of differences in the comparisons and outcomes between studies. Data was extracted by two authors and compared prior to insertion into the review to ensure accuracy.</P>
<P>It was intended that, if there were studies that included people with mixed incontinence a subgroup analysis was to be done to see if the effect was different in those with mixed incontinence, but this was not possible. Similarly, it was not possible to do a subgroup analysis dividing participants into neurogenic OAB and idiopathic OAB syndrome groups, or to assess the effect of different formulations of botulinum toxin. Although several studies separated idiopathic OAB and neurogenic OAB participants, the large variability in study design made pooling of these data impossible. For example outcome measures, doses of botulinum toxin, and different follow up time periods made the studies impossible to compare quantitatively. As many studies were only in abstract form, quantitative data were often limited. Study authors were contacted to try and obtain further results or statistical analysis as well as to confirm multiple publications and study methods. No further details were obtained from any of the authors contacted.</P>
<P>Data was synthesised across studies where possible, but limited in some cases due to differing designs and outcome measures. Some studies had multiple publications; these were treated as a single source of data. Due to limited published data some Standard Deviations for the meta-analysis were calculated from P values using the formula found in section 7.7.3.3 of the Cochrane handbook.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-11-09 17:31:21 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-11-09 17:26:12 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Search results</HEADING>
<P>For the original review 19 publications were identified in the literature search of which eight were single reports of eight included studies and 11 reports were excluded (for details of the exclusions with reasons please see the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). Updated searches in January 2009 and February 2010 identified a further 51 publications. Of these 20 were reports of 11 new studies and 20 were extra reports of four of the already included studies; the remaining 11 publications were excluded (detailed in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). In total 19 unique studies were identified as meeting the inclusion criteria (including eight from the original review) and the other publications were excluded from the analysis on the basis of their abstract or full review of the publication. Nine of the included studies were only available as abstracts (<LINK REF="STD-Finney-2006" TYPE="STUDY">Finney 2006</LINK>; <LINK REF="STD-Grise-2008" TYPE="STUDY">Grise 2008</LINK>; <LINK REF="STD-Herschorn-2009" TYPE="STUDY">Herschorn 2009</LINK>; <LINK REF="STD-Karsenty-2005" TYPE="STUDY">Karsenty 2005</LINK>; <LINK REF="STD-King-2007" TYPE="STUDY">King 2007</LINK>; <LINK REF="STD-Lucioni-2008" TYPE="STUDY">Lucioni 2008</LINK>; <LINK REF="STD-Moore-2009" TYPE="STUDY">Moore 2009</LINK>; <LINK REF="STD-Thavaseelan-2005" TYPE="STUDY">Thavaseelan 2005</LINK>; <LINK REF="STD-Truzzi-2004" TYPE="STUDY">Truzzi 2004</LINK>) and nine reported data in more than one article but derived from the same study (<LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK>; <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK>; <LINK REF="STD-Ghei-2005" TYPE="STUDY">Ghei 2005</LINK>; <LINK REF="STD-Gousse-2005" TYPE="STUDY">Gousse 2005</LINK>; <LINK REF="STD-Herschorn-2009" TYPE="STUDY">Herschorn 2009</LINK>; <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>; <LINK REF="STD-Kuo-2007" TYPE="STUDY">Kuo 2007</LINK>; <LINK REF="STD-Sahai-2005" TYPE="STUDY">Sahai 2005</LINK>; <LINK REF="STD-Schurch-2005" TYPE="STUDY">Schurch 2005</LINK>). The flow of literature through the assessment process is shown in the PRISMA flow chart <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Included studies</HEADING>
<P>The included studies were: <LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK>; <LINK REF="STD-Ehren-2007" TYPE="STUDY">Ehren 2007</LINK>; <LINK REF="STD-Finney-2006" TYPE="STUDY">Finney 2006</LINK>; <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK>; <LINK REF="STD-Ghei-2005" TYPE="STUDY">Ghei 2005</LINK>; <LINK REF="STD-Giannantoni-2004" TYPE="STUDY">Giannantoni 2004</LINK>; <LINK REF="STD-Gousse-2005" TYPE="STUDY">Gousse 2005</LINK>; <LINK REF="STD-Grise-2008" TYPE="STUDY">Grise 2008</LINK>; <LINK REF="STD-Herschorn-2009" TYPE="STUDY">Herschorn 2009</LINK>; <LINK REF="STD-Karsenty-2005" TYPE="STUDY">Karsenty 2005</LINK>; <LINK REF="STD-King-2007" TYPE="STUDY">King 2007</LINK>; <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>; <LINK REF="STD-Kuo-2007" TYPE="STUDY">Kuo 2007</LINK>; <LINK REF="STD-Lucioni-2008" TYPE="STUDY">Lucioni 2008</LINK>; <LINK REF="STD-Moore-2009" TYPE="STUDY">Moore 2009</LINK>; <LINK REF="STD-Sahai-2005" TYPE="STUDY">Sahai 2005</LINK>; <LINK REF="STD-Schurch-2005" TYPE="STUDY">Schurch 2005</LINK>; <LINK REF="STD-Thavaseelan-2005" TYPE="STUDY">Thavaseelan 2005</LINK>; <LINK REF="STD-Truzzi-2004" TYPE="STUDY">Truzzi 2004</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Study objectives</HEADING>
<P>Ten of the included studies compared intravesical botulinum toxin with placebo. Two studies used botulinum toxin type B (<LINK REF="STD-Ghei-2005" TYPE="STUDY">Ghei 2005</LINK>; <LINK REF="STD-Moore-2009" TYPE="STUDY">Moore 2009</LINK>). The other eight studies used botulinum toxin type A; two of these compared 300U of botulinum toxin type A with placebo (<LINK REF="STD-Herschorn-2009" TYPE="STUDY">Herschorn 2009</LINK>; <LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK>), two compared 200 U of botulinum toxin type A with placebo (<LINK REF="STD-King-2007" TYPE="STUDY">King 2007</LINK>; <LINK REF="STD-Sahai-2005" TYPE="STUDY">Sahai 2005</LINK>), two compared both 300 U and 200 U with placebo (<LINK REF="STD-Schurch-2005" TYPE="STUDY">Schurch 2005</LINK>; <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK>) and two used 500 U of Dysport (a trade name for an extract of botulinum toxin type A) versus placebo (<LINK REF="STD-Ehren-2007" TYPE="STUDY">Ehren 2007</LINK>; <LINK REF="STD-Finney-2006" TYPE="STUDY">Finney 2006</LINK>). Seven of the included studies compared different doses of botulinum toxin type A with or without a placebo arm (<LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK>; <LINK REF="STD-Gousse-2005" TYPE="STUDY">Gousse 2005</LINK>; <LINK REF="STD-Grise-2008" TYPE="STUDY">Grise 2008</LINK>; <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>; <LINK REF="STD-Schurch-2005" TYPE="STUDY">Schurch 2005</LINK>; <LINK REF="STD-Thavaseelan-2005" TYPE="STUDY">Thavaseelan 2005</LINK>; <LINK REF="STD-Truzzi-2004" TYPE="STUDY">Truzzi 2004</LINK>). One study compared 300 U of botulinum toxin type A with the other pharmacological treatment of intravesical resiniferatoxin (<LINK REF="STD-Giannantoni-2004" TYPE="STUDY">Giannantoni 2004</LINK>), and three studies compared different injection techniques of botulinum toxin type A. <LINK REF="STD-Karsenty-2005" TYPE="STUDY">Karsenty 2005</LINK> used different numbers of injection sites, <LINK REF="STD-Kuo-2007" TYPE="STUDY">Kuo 2007</LINK> compared intradetrusor, suburothelial and bladder base injections and <LINK REF="STD-Lucioni-2008" TYPE="STUDY">Lucioni 2008</LINK> compared different injection volumes. All studies used a single treatment with botulinum toxin except <LINK REF="STD-Gousse-2005" TYPE="STUDY">Gousse 2005</LINK> where the participants were re-injected every six months and <LINK REF="STD-Herschorn-2009" TYPE="STUDY">Herschorn 2009</LINK> where an open label injection was offered to all participants at 36 weeks. Details can be found in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Design and sample size</HEADING>
<P>The included studies were small, ranging from 14 to 77 participants with an average of 37 participants. The majority of the studies were double blinded and all were randomised. Two of the studies were of a crossover design, <LINK REF="STD-Ghei-2005" TYPE="STUDY">Ghei 2005</LINK> crossed over at six weeks and <LINK REF="STD-Moore-2009" TYPE="STUDY">Moore 2009</LINK> crossed at 10 weeks. Only a few of the studies mentioned power calculations.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>The majority of included studies involved participants with neurogenic OAB, often due to spinal cord injury or multiple sclerosis. Seven studies included only participants with idiopathic OAB (<LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK>; <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK>; <LINK REF="STD-Gousse-2005" TYPE="STUDY">Gousse 2005</LINK>; <LINK REF="STD-King-2007" TYPE="STUDY">King 2007</LINK>; <LINK REF="STD-Kuo-2007" TYPE="STUDY">Kuo 2007</LINK>; <LINK REF="STD-Moore-2009" TYPE="STUDY">Moore 2009</LINK>; <LINK REF="STD-Sahai-2005" TYPE="STUDY">Sahai 2005</LINK>). <LINK REF="STD-Caruso-2009" TYPE="STUDY">Caruso 2009</LINK> (a subgroup from <LINK REF="STD-Gousse-2005" TYPE="STUDY">Gousse 2005</LINK>) and <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK> specified that all included patients had OAB with incontinence.  The majority of participants had symptoms refractory to antimuscarinics or did not tolerate the medication as an inclusion criteria. One study required all participants to self catheterise, four times a day post-procedure to measure post-void residual volume (<LINK REF="STD-Truzzi-2004" TYPE="STUDY">Truzzi 2004</LINK>). In three studies the participants had OAB of mixed aetiology (<LINK REF="STD-Ghei-2005" TYPE="STUDY">Ghei 2005</LINK>; <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>; <LINK REF="STD-Truzzi-2004" TYPE="STUDY">Truzzi 2004</LINK>). Demographic features were often not clear from the abstract publications. Where stated, participants were of mixed gender except in <LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK> and <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK>, which studied women only. The age ranges appeared to be wide across the studies, from 14 years (<LINK REF="STD-Truzzi-2004" TYPE="STUDY">Truzzi 2004</LINK>), to 89 years in (<LINK REF="STD-Lucioni-2008" TYPE="STUDY">Lucioni 2008</LINK>). The studies varied in whether or not participants were allowed to continue antimuscarinic medications for OAB during the follow up period. Details of the participants demographics were often poorly documented in the studies and the available details can be found in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Outcomes</HEADING>
<P>Outcome measures included in the trial reports varied making it difficult to quantitatively compare data between studies. Often only measures of statistical significance were reported, sometimes with measures of difference, but often no group data. Results reported in several abstract publications were often unusable for comparison as full details of outcome measures had not been reported. There were, however, consistent themes with researchers most commonly utilising established questionnaires to report quantification of quality of life, incontinence episodes, and objective urodynamic measurements.  In total, ten studies measured number of incontinence episodes (<LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK>; <LINK REF="STD-Ehren-2007" TYPE="STUDY">Ehren 2007;</LINK> <LINK REF="STD-Finney-2006" TYPE="STUDY">Finney 2006</LINK>; <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK>; <LINK REF="STD-Ghei-2005" TYPE="STUDY">Ghei 2005</LINK>; <LINK REF="STD-Giannantoni-2004" TYPE="STUDY">Giannantoni 2004</LINK>; <LINK REF="STD-Karsenty-2005" TYPE="STUDY">Karsenty 2005</LINK>; <LINK REF="STD-King-2007" TYPE="STUDY">King 2007</LINK>; <LINK REF="STD-Kuo-2007" TYPE="STUDY">Kuo 2007</LINK>; <LINK REF="STD-Schurch-2005" TYPE="STUDY">Schurch 2005</LINK>), eleven measured quality of life (<LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK>; <LINK REF="STD-Gousse-2005" TYPE="STUDY">Gousse 2005</LINK>; <LINK REF="STD-Ehren-2007" TYPE="STUDY">Ehren 2007</LINK>; <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK>; <LINK REF="STD-Ghei-2005" TYPE="STUDY">Ghei 2005</LINK>; <LINK REF="STD-Herschorn-2009" TYPE="STUDY">Herschorn 2009</LINK>; <LINK REF="STD-Karsenty-2005" TYPE="STUDY">Karsenty 2005</LINK>; <LINK REF="STD-Lucioni-2008" TYPE="STUDY">Lucioni 2008</LINK>; <LINK REF="STD-Moore-2009" TYPE="STUDY">Moore 2009</LINK>; <LINK REF="STD-Sahai-2005" TYPE="STUDY">Sahai 2005</LINK>; <LINK REF="STD-Schurch-2005" TYPE="STUDY">Schurch 2005</LINK>), and ten used urodynamic studies as outcomes (<LINK REF="STD-Ehren-2007" TYPE="STUDY">Ehren 2007</LINK>; <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK>; <LINK REF="STD-Giannantoni-2004" TYPE="STUDY">Giannantoni 2004</LINK>; <LINK REF="STD-Herschorn-2009" TYPE="STUDY">Herschorn 2009</LINK>; <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>; <LINK REF="STD-Kuo-2007" TYPE="STUDY">Kuo 2007</LINK>; <LINK REF="STD-Lucioni-2008" TYPE="STUDY">Lucioni 2008</LINK>; <LINK REF="STD-Sahai-2005" TYPE="STUDY">Sahai 2005</LINK>; <LINK REF="STD-Schurch-2005" TYPE="STUDY">Schurch 2005</LINK>; <LINK REF="STD-Thavaseelan-2005" TYPE="STUDY">Thavaseelan 2005</LINK>). Six studies used subjective recording of symptoms such as frequency and nocturia (<LINK REF="STD-Finney-2006" TYPE="STUDY">Finney 2006</LINK>; <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK>; <LINK REF="STD-Ghei-2005" TYPE="STUDY">Ghei 2005</LINK>; <LINK REF="STD-King-2007" TYPE="STUDY">King 2007</LINK>; <LINK REF="STD-Kuo-2007" TYPE="STUDY">Kuo 2007</LINK>; <LINK REF="STD-Sahai-2005" TYPE="STUDY">Sahai 2005</LINK>).  <LINK REF="STD-Grise-2008" TYPE="STUDY">Grise 2008</LINK> and <LINK REF="STD-Truzzi-2004" TYPE="STUDY">Truzzi 2004</LINK> used continence as an outcome. Two papers measured pad weights (<LINK REF="STD-Finney-2006" TYPE="STUDY">Finney 2006</LINK>; <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK>). One study each measured number of catheterizations (<LINK REF="STD-Giannantoni-2004" TYPE="STUDY">Giannantoni 2004</LINK>), pad numbers (<LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK>), and antimuscarinic medication consumption (<LINK REF="STD-Ehren-2007" TYPE="STUDY">Ehren 2007</LINK>). Only four studies included post void residual volume (PVR) as an outcome (<LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK>; <LINK REF="STD-Finney-2006" TYPE="STUDY">Finney 2006</LINK>; <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK>; <LINK REF="STD-Sahai-2005" TYPE="STUDY">Sahai 2005</LINK>). Details of the outcomes measured can be found in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Follow up</HEADING>
<P>All studies followed participants after a single occasion of intravesical injection of botulinum toxin, except <LINK REF="STD-Gousse-2005" TYPE="STUDY">Gousse 2005</LINK> where the participants were re-injected every six months and <LINK REF="STD-Herschorn-2009" TYPE="STUDY">Herschorn 2009</LINK> where the participants were offered open label use of botulinum toxin at 36 weeks. The length of predetermined follow up varied from six weeks in <LINK REF="STD-Ghei-2005" TYPE="STUDY">Ghei 2005</LINK> to 24 months in <LINK REF="STD-Gousse-2005" TYPE="STUDY">Gousse 2005</LINK>. In several studies the follow up was ongoing.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-11-09 17:26:29 +0000" MODIFIED_BY="[Empty name]">
<P>Details of study methodology were frequently unclear, particularly in the abstract publications.  The <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> explore this in more detail.</P>
<SUBSECTION>
<HEADING LEVEL="3">Allocation</HEADING>
<P>Allocation concealment was clear in <LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK>, <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK>, <LINK REF="STD-Ghei-2005" TYPE="STUDY">Ghei 2005</LINK>; <LINK REF="STD-Gousse-2005" TYPE="STUDY">Gousse 2005</LINK>, and <LINK REF="STD-Sahai-2005" TYPE="STUDY">Sahai 2005</LINK>. There appeared to be no allocation concealment in <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>.  Allocation concealment was unclear in the remaining studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>
<LINK REF="STD-Truzzi-2004" TYPE="STUDY">Truzzi 2004</LINK> and <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK> describe single-blinding of patients in their studies.  <LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK> and <LINK REF="STD-Moore-2009" TYPE="STUDY">Moore 2009</LINK> report blinding of patients, clinicians, and study coordinators or assessors.  Clinicians and patients were blinded in <LINK REF="STD-Ghei-2005" TYPE="STUDY">Ghei 2005</LINK>, <LINK REF="STD-Finney-2006" TYPE="STUDY">Finney 2006</LINK>, and <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK>.  Assessors and patients were blinded in <LINK REF="STD-Sahai-2005" TYPE="STUDY">Sahai 2005</LINK> and <LINK REF="STD-Schurch-2005" TYPE="STUDY">Schurch 2005</LINK>.  <LINK REF="STD-Giannantoni-2004" TYPE="STUDY">Giannantoni 2004</LINK> was unblinded. The remaining ten studies do not give clear details of the blinding process. Blinding of clinicians, and in some cases patients, in studies comparing different injection or administration techniques may be impossible.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Follow up and exclusions</HEADING>
<P>There were no concerns over the exclusion of participants. All the included studies were of a small size ranging from 14 to 77 participants only a few of the studies performed power calculations to ensure appropriate numbers of participants. Several studies included participants who, as a group, had OAB of mixed aetiology. There were few dropouts reported in the studies. <LINK REF="STD-Ghei-2005" TYPE="STUDY">Ghei 2005</LINK> mentioned two patients who did not complete follow up due to an adverse event. The data still qualified for analysis, however, as this was the only study to describe analysis on an intention-to-treat basis. The only other reported withdrawals from treatment were seven participants at the 12 week follow up stage in <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK> and four from <LINK REF="STD-Ehren-2007" TYPE="STUDY">Ehren 2007</LINK>, all from their respective placebo groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Additional risk of bias</HEADING>
<P>Botulinum toxin was provided for study use in <LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK>, <LINK REF="STD-Gousse-2005" TYPE="STUDY">Gousse 2005</LINK>, <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK> and <LINK REF="STD-Kuo-2007" TYPE="STUDY">Kuo 2007</LINK>. Pharmaceutical companies partly or fully financed <LINK REF="STD-Ehren-2007" TYPE="STUDY">Ehren 2007</LINK>, <LINK REF="STD-Finney-2006" TYPE="STUDY">Finney 2006</LINK>, <LINK REF="STD-Herschorn-2009" TYPE="STUDY">Herschorn 2009</LINK>, <LINK REF="STD-King-2007" TYPE="STUDY">King 2007</LINK>, and <LINK REF="STD-Lucioni-2008" TYPE="STUDY">Lucioni 2008</LINK>. A disclosure of relationship with pharmaceutical company was made by authors of <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK>, <LINK REF="STD-Sahai-2005" TYPE="STUDY">Sahai 2005</LINK>, and <LINK REF="STD-Schurch-2005" TYPE="STUDY">Schurch 2005</LINK>. Authors explicitly stated that they had no disclosures or conflicts of interest in <LINK REF="STD-Grise-2008" TYPE="STUDY">Grise 2008</LINK>, and <LINK REF="STD-Moore-2009" TYPE="STUDY">Moore 2009</LINK>.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-11-09 17:31:21 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Objective1: Intravesical injection of botulinum toxin is better than placebo or no treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Quantification of symptoms</HEADING>
<P>In <LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK> patient perception of symptoms was significantly improved in the botulinum toxin group throughout 12 months follow up (P &lt; 0.0001). Sixty percent of patients achieved a subjective clinical response based on Patient Global Impression of Improvement (PGI-I) measurement. Number of incontinence episodes was also significantly reduced at one month (P &lt; 0.0001). <LINK REF="STD-Ehren-2007" TYPE="STUDY">Ehren 2007</LINK> demonstrated a significantly lower rate of Tolterodine consumption at all time points studied (P &lt; 0.003), and significantly fewer days with incontinence episodes (P &#8804; 0.01). <LINK REF="STD-Finney-2006" TYPE="STUDY">Finney 2006</LINK> showed significant improvements in pad weights, daytime frequency, and antimuscarinic requirements from 12 through to 36 weeks follow up (P &lt; 0.05). There was no difference in nocturia or incontinence episodes. Incontinence episodes in <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK> were significantly reduced (P &lt; 0.01), along with pad weight (P = 0.02), and nocturia (P = 0.02). Daytime frequency was unchanged. <LINK REF="STD-Ghei-2005" TYPE="STUDY">Ghei 2005</LINK> also reported a significant reduction in weekly incontinence episodes and frequency compared with placebo with the shorter acting botulinum toxin type B at two weeks (P = 0.001, P = 0.033 respectively). <LINK REF="STD-Herschorn-2009" TYPE="STUDY">Herschorn 2009</LINK> reported fewer incontinence episodes at six and 24 weeks (P &lt; 0.01). A significant reduction in incontinence episodes was also found in <LINK REF="STD-King-2007" TYPE="STUDY">King 2007</LINK> (P = 0.0005), along with nocturia (P = 0.0032). There was a trend towards reduced daytime frequency that was not statistically significant. <LINK REF="STD-Moore-2009" TYPE="STUDY">Moore 2009</LINK> found a significant difference in incontinence episodes (P = 0.03), pad usage (P = 0.03), and frequency (P = 0.008) in the botulinum toxin group at two weeks, while a trend towards reduced nocturia was not significant. <LINK REF="STD-Sahai-2005" TYPE="STUDY">Sahai 2005</LINK> found significant improvements in frequency (P = 0.0001), urgency (P = 0.0047), and urge incontinence (P = 0.0284) at four weeks which was sustained until 12 weeks, although the improvement in urgency lost statistical significance after four weeks. Incontinence episodes were significantly reduced up to 24 weeks (P &lt; 0.05) in <LINK REF="STD-Schurch-2005" TYPE="STUDY">Schurch 2005</LINK>.</P>
<P>Graphical representation of the statistical meta-analysis for urinary frequency and incontinence episodes is presented in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. The meta-analysis for urinary frequency favoured botulinum toxin at both the four to six week and 12 week follow up points. The mean difference was a reduction in urinary frequency of - 6.50 episodes per day (- 8.92 to - 4.07), (P = &lt; 0.00001) at 4 to 6 weeks. At 12 weeks, the mean difference was a reduction in urinary frequency of - 3.37 episodes per day (- 5.15 to - 1.59), (P = 0.0002). . The meta-analysis for incontinence episodes favoured botulinum toxin at both four to six week and 12 week follow up points. The mean difference was a reduction in incontinence episodes of -1.58 (- 2.16 to -1.01), (P = 0.00001) at 4 to 6 weeks. At 12 weeks, the mean difference was a reduction in incontinence episodes of - 2.74 (- 4.47 to -1.01), (P = 0.002).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinicians' measures (Urodynamics)</HEADING>
<P>
<LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK> was discontinued due to a high rate of urinary retention defined as a post-void residual volume (PVR) of greater than 200 ml. This was seen in 43% of patients in the botulinum toxin group. <LINK REF="STD-Ehren-2007" TYPE="STUDY">Ehren 2007</LINK> found an improvement in bladder capacity at six (P &lt; 0.001) and 12 weeks (P = 0.026), but no significant difference at 26 weeks (P = 0.064). Maximum detrusor pressure (MDP) was significantly lower in the botulinum toxin group (P &lt; 0.01) at all time periods. <LINK REF="STD-Finney-2006" TYPE="STUDY">Finney 2006</LINK> demonstrated a significant increase in maximum cystometric capacity (MCC) in the botulinum toxin group (P = 0.016) at six weeks. PVR was also significantly increased in the botulinum toxin group (P = 0.003), along with detrusor pressure at first overactive contraction (P = 0.001). PVR was also increased in <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK> (P &lt; 0.01), but no difference was found in MCC, volume at first overactive contraction, peak flow, or detrusor pressure at peak flow. A PVR of greater than 200 ml was seen in 26.6% of patients at six weeks. A significant improvement in volume at first overactive contraction was reported in <LINK REF="STD-Herschorn-2009" TYPE="STUDY">Herschorn 2009</LINK> through until week 24 (P &lt; 0.01), along with volume at MDP (P &lt; 0.05). <LINK REF="STD-Sahai-2005" TYPE="STUDY">Sahai 2005</LINK> reported an increase in PVR at four weeks (P = 0.024), but not at 12 weeks (P = 0.41). Volume at first overactive contraction was again increased at all time points (P &#8804; 0.024). <LINK REF="STD-Schurch-2005" TYPE="STUDY">Schurch 2005</LINK> demonstrated an increase in MCC and volume at first overactive contraction, and a decrease in MDP at all time points to week 24 (P &lt; 0.05 for all measures).</P>
<P>A meta-analysis of the available data for PVR is presented in <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>. The meta-analysis for change in PVR favours placebo with an increase of PVR of 70.22 ml (30.63 to 109.81) in the botulinum toxin group, (P = 0.0005).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Health status and quality of life questionnaires</HEADING>
<P>
<LINK REF="STD-Ehren-2007" TYPE="STUDY">Ehren 2007</LINK> used the Qualiveen questionnaire as a quality of life measure and found a significant decrease in bother score associated with symptoms including incontinence episodes (P &lt; 0.00018) and disturbed nights (P = 0.033). Both the Urinary Distress Inventory- 6 (UDI-6) and the Incontinence Impact Questionnaire (IIQ-7) symptom scores showed improvement in <LINK REF="STD-Finney-2006" TYPE="STUDY">Finney 2006</LINK> (P &lt; 0.02, P &#8804; 0.01 respectively). <LINK REF="STD-Ghei-2005" TYPE="STUDY">Ghei 2005</LINK> reported significant improvements compared with placebo in some of the domains of the King's Health Questionnaire, including impact on life, incontinence impact, and incontinence severity measures (P = 0.004, P = 0.03, P = 0.02 respectively). <LINK REF="STD-Herschorn-2009" TYPE="STUDY">Herschorn 2009</LINK> and <LINK REF="STD-Schurch-2005" TYPE="STUDY">Schurch 2005</LINK> demonstrated improvement in Incontinence Quality of Life Questionnaire (IQOL) score compared with placebo at all time points (P &lt; 0.05, and P &lt; 0.05 respectively). <LINK REF="STD-Moore-2009" TYPE="STUDY">Moore 2009</LINK> used UDI-6 and the King's Health Questionnaire and found improvements in both at two weeks (P = 0.02, no P value given for any sub-scale of the King's Health Questionnaire). In <LINK REF="STD-Sahai-2005" TYPE="STUDY">Sahai 2005</LINK> IIQ-7 and UDI-6 were both significantly improved at four and 12 weeks (P &#8804; 0.025, P &#8804; 0.0003 respectively). Although some papers used the same quality of life measurement tools, there were none that used comparable methods of treatment. As such no pooling of quality of life data could be performed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Objective 2: Intravesical injection of botulinum toxin is better than other pharmacological interventions</HEADING>
<P>There was only one trial identified that addressed this objective. <LINK REF="STD-Giannantoni-2004" TYPE="STUDY">Giannantoni 2004</LINK> compared 300 U of intravesical botulinum toxin type A with instillation of resiniferatoxin. They reported a significant decrease in rates of incontinence with botulinum toxin compared with resiniferatoxin at six, 12 and 18 months. A significant increase in MCC and decrease in MDP measured by urodynamics compared with resiniferatoxin at six, 12 and 18 months (taken from the report of study) was found. They also reported a significant increase in PVR in the botulinum toxin group at all time points.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Objective 3: Intravesical injection of botulinum toxin is better than other non-pharmacological interventions</HEADING>
<P>There were no trials identified that addressed this objective.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Objective 4: Higher doses of intravesical botulinum toxin are better than lower doses</HEADING>
<P>There were six trials identified that specifically addressed this objective (<LINK REF="STD-Gousse-2005" TYPE="STUDY">Gousse 2005</LINK>; <LINK REF="STD-Grise-2008" TYPE="STUDY">Grise 2008</LINK>; <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>; <LINK REF="STD-Schurch-2005" TYPE="STUDY">Schurch 2005</LINK>; <LINK REF="STD-Thavaseelan-2005" TYPE="STUDY">Thavaseelan 2005</LINK>; <LINK REF="STD-Truzzi-2004" TYPE="STUDY">Truzzi 2004</LINK>). Although <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK> used 200 U and 300 U the results in the currently published study pooled these results so no comparative conclusion could be made. The unpooled data will hopefully be available once the study is finished. <LINK REF="STD-Gousse-2005" TYPE="STUDY">Gousse 2005</LINK> compared 100 U botulinum toxin type A with 150 U botulinum toxin type A with up to 50 patients and noted no difference in frequency, PVR, MDP, peak flow, MCC, quality of life, and incontinence, which were all improved in both groups compared to baseline. There was a non-significant trend suggesting the higher dose led to more patients achieving complete dryness. In a subgroup analysis (<LINK REF="STD-Caruso-2009" TYPE="STUDY">Caruso 2009</LINK>) of patients with idiopathic OAB and urge incontinence a significant difference was seen in incontinence episodes with 150 U superior to 100 U (P=0.02). <LINK REF="STD-Grise-2008" TYPE="STUDY">Grise 2008</LINK> compared 500 U with 750 U (Dysport) and found a non-significant trend towards better continence with 750 U. <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK> compared 100 U with 150 U and 200 U showing similar efficacy between the groups. The 150 U and 200 U groups demonstrating significantly higher bladder capacity and PVR while the duration of effect was shorter for the 100 U group. Mean therapeutic effect in the 200 U group was 6.7 months versus 5.5 months in the 150 U group and 3.5 months in the 100 U group. There was a significantly higher rate of urinary retention associated with the higher doses (P=0.011). <LINK REF="STD-Schurch-2005" TYPE="STUDY">Schurch 2005</LINK> compared 200 U and 300 U with placebo, and showed significant improvements in both botulinum toxin groups compared with placebo but found no clear difference between the two doses. <LINK REF="STD-Thavaseelan-2005" TYPE="STUDY">Thavaseelan 2005</LINK> compared 200 U with 300 U but did not comment on any difference between the two groups. <LINK REF="STD-Truzzi-2004" TYPE="STUDY">Truzzi 2004</LINK> compared 100 U with 300 U and suggested a trend towards better continence in the 300 U group, but did not report on statistical significance. While many of the studies used similar doses, none compared doses in a manner that allowed data pooling.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Objective 5: Intravesical injection of botulinum toxin combined with other treatments is better than other treatments alone</HEADING>
<P>There were no trials identified that specifically addressed this objective.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Objective 6: One formulation of botulinum toxin is better than another</HEADING>
<P>There were no trials identified that specifically addressed this objective.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Objective 7: One injection technique is better than another</HEADING>
<P>There were three studies identified that addressed this objective. <LINK REF="STD-Karsenty-2005" TYPE="STUDY">Karsenty 2005</LINK> compared two different techniques of injection of 300 U of botulinum toxin type A. They compared 10 versus 30 injection sites and reported a significant reduction in post-procedure pain in the group receiving 10 injections. There were no significant differences found in any other measures including incontinence episodes or MCC (taken from the report of study). <LINK REF="STD-Kuo-2007" TYPE="STUDY">Kuo 2007</LINK> investigated suburothelial, intra-detrusor and bladder base injections with 15 participants in each group. Urgency was improved in all groups but in the bladder base group there was no increase in MCC or PVR. <LINK REF="STD-Lucioni-2008" TYPE="STUDY">Lucioni 2008</LINK> compared 200 U of botulinum toxin with injection volumes of 0.1, 0.5 and 1.0 cc per injection but with the same number of injections and found no significant difference between the groups quality of life using IIQ-7 and UDI-6. All groups had significant increases in MCC. In the 1.0 cc group there was no increase in bladder compliance, which was seen in the other two groups. As none of the studies had comparable injection techniques, data could not be pooled.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>
<LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK> was halted before completion due to unacceptable adverse effects. Twelve of 28 patients in the treatment arm developed urinary retention requiring CIC, and 44% had diagnosed urinary tract infections (UTI).  It should be noted that <LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK> had a robust and rigorous follow up schedule monitoring these adverse events.  <LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK> also reported a few miscellaneous adverse events of similar number in placebo and treatment arms that seemed unrelated to their treatment.  In <LINK REF="STD-Ehren-2007" TYPE="STUDY">Ehren 2007</LINK> one of 17 treatment patients, who had ceased their usual warfarin for three days pre-procedure developed haematuria requiring 24 hours of catheterization before resolving.  <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK> also had a single patient with haematuria requiring overnight hospital admission and continuous bladder irrigation, but of further investigation was found to be likely bleeding from ureteric varicosities.  Four patients developed high PVR after injection of botulinum toxin in <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK>, and one of these went on to perform CIC. This patient reported a better quality of life with CIC than with the symptoms of OAB prior to botulinum toxin treatment.</P>
<P>Of the adverse events mentioned in the included studies, <LINK REF="STD-Ghei-2005" TYPE="STUDY">Ghei 2005</LINK> reported two patients who needed to commence CIC for six weeks after developing urinary retention. <LINK REF="STD-Gousse-2005" TYPE="STUDY">Gousse 2005</LINK> reported one participant, who presumably did not undertake CIC, with a transient rise of post-void residual volume to 200 ml and development of urinary tract infection. <LINK REF="STD-Herschorn-2009" TYPE="STUDY">Herschorn 2009</LINK> reported two patients in the botulinum toxin group that experienced transient upper body weakness. <LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK> included adverse events as an endpoint for their study of comparative doses of botulinum toxin, and found in the 200 U and 150 U groups, that six, and two patients respectively developed urinary retention. Four, and two patients were diagnosed with UTI, while those in the 100 U group had no reported retention or UTI.  <LINK REF="STD-Kuo-2007" TYPE="STUDY">Kuo 2007</LINK> reported adverse events from their total group of 45 patients that in the suburothelial injection group seven developed dysuria, two urinary retention, two UTI, one gross haematuria, and one suffered post-treatment pain.  In the detrusor injection group five developed dysuria, two urinary retention, one UTI, and one post-treatment pain.  In the bladder base injection group, two developed dysuria, and one each developed urinary retention, UTI, and post-treatment pain.  <LINK REF="STD-Lucioni-2008" TYPE="STUDY">Lucioni 2008</LINK> reported one patient in each of the three treatment arms developing urinary retention from the total group of 30 patients.  <LINK REF="STD-Sahai-2005" TYPE="STUDY">Sahai 2005</LINK> reported three patients needing to commence CIC for reasons that were not mentioned. <LINK REF="STD-Schurch-2005" TYPE="STUDY">Schurch 2005</LINK> reported a urinary tract infection rate of approximately 25% in their participants who all performed regular self catheterization prior to intervention. This was commented on as being similar to the accepted infection rate in people who undertake CIC. This study also reported transient post-procedure pain in one placebo and two 300 U botulinum toxin patients of the 59 patients in total. </P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-11-09 17:29:12 +0000" MODIFIED_BY="[Empty name]">
<P>An increasing body of randomised data has emerged since the original review. During this same period, the use of botulinum toxin has become more mainstream for treating OAB. In this review a total of 14 new studies have been identified that meet the inclusion criteria, bringing the total number of included studies to 19. The studies are still universally small, with the maximum number of 77 participants in any individual study. There is an increase in data regarding idiopathic OAB, and data with an emphasis on wet versus dry OAB. It should be noted that in all cases the participants are not treatment naive, but are regarded as refractory to conservative measures and anti-muscarinics.</P>
<P>There is now further support from the literature for the efficacy of botulinum toxin versus placebo. A significant clinical response may be seen in up to 60 to 90% of patients (<LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK>; <LINK REF="STD-Gousse-2005" TYPE="STUDY">Gousse 2005</LINK>). Of patients with OAB with incontinence, up to 66% may achieve complete continence (<LINK REF="STD-Grise-2008" TYPE="STUDY">Grise 2008</LINK>). The duration of effect seem to vary widely, partly due to variation in outcome measures, and perhaps dosage. Benefits may be seen for between three and 12 months (<LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>; <LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK>). There are still no randomised comparisons between different formulations of botulinum toxin, but it seems that botulinum toxin type A has a more durable effect than botulinum toxin type B which seems to be limited to less than 10 weeks (<LINK REF="STD-Moore-2009" TYPE="STUDY">Moore 2009</LINK>). Many studies did not comment on duration of effect at all due to short follow up. One study investigated repeated injections of botulinum toxin, finding this to be safe, with no evidence of patients becoming refractory to treatment.</P>
<P>There are still no eligible study that compare or combine botulinum toxin with other treatments, apart from one showing superiority to intravesical resiniferatoxin (<LINK REF="STD-Giannantoni-2004" TYPE="STUDY">Giannantoni 2004</LINK>).</P>
<P>In the majority of studies the authors avoid injecting the trigone, however, <LINK REF="STD-Moore-2009" TYPE="STUDY">Moore 2009</LINK> investigated injecting the trigone and found no evidence of vesico-ureteric reflux.</P>
<P>The optimally safe and effective dose of botulinum toxin is still unproven, with only one small study suggesting that a lower dose of 100 U may have comparable efficacy to and improved safety over 200 U and 300 U (<LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>).</P>
<P>
<LINK REF="STD-Cohen-2007" TYPE="STUDY">Cohen 2007</LINK> reported extra data from the <LINK REF="STD-Gousse-2005" TYPE="STUDY">Gousse 2005</LINK> study on treatment tolerability. They found that in the office setting, 26 of 27 patients tolerated botulinum toxin administration under local anaesthetic only.</P>
<P>There are consistent improvements in urodynamic parameters with botulinum toxin. Improved MCC and MDP have been reported by almost all authors who measured these variables. A significant increase in MCC was found in all studies that measured this except for <LINK REF="STD-Flynn-2009" TYPE="STUDY">Flynn 2009</LINK> which reported a non-significant trend towards increased MCC. Those studies that measured MDP all found that it was significantly decreased after botulinum toxin treatment.</P>
<P>Since the first review an increasing number of studies have measured PVR, in response to the early findings that PVR may be increased after botulinum toxin. It has been found that some patients may require CIC after botulinum toxin. The need for CIC seems related to how aggressively patients are investigated for PVR and the pre-determined volume threshold for commencing CIC. Significant increases in PVR may be seen in up to 72% of patients, however, this may in many cases not be clinically significant (<LINK REF="STD-Kuo-2006" TYPE="STUDY">Kuo 2006</LINK>). Higher rates of increased PVR may be found with higher doses of botulinum toxin. There was variation in the threshold for commencing CIC. Some studies had a set point for CIC, while others only commenced CIC if patients became symptomatic, and one required all participants to perform regular CIC (<LINK REF="STD-Truzzi-2004" TYPE="STUDY">Truzzi 2004</LINK>). Some studies included participants that were already performing CIC prior to treatment (<LINK REF="STD-Schurch-2005" TYPE="STUDY">Schurch 2005</LINK>). Although the need to commence CIC is considered a significant adverse effect by many, one study demonstrated a similar improvement in quality of life from baseline in patients after botulinum toxin treatment whether they had to commence CIC or not (<LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK>). It should be remembered that all participants in the included studies had failed other conservative management options and were considered to have severe OAB. Many were incontinent prior to treatment, and it may be that patients prefer CIC to incontinence in some cases.</P>
<P>Adverse events following botulinum toxin administration may be related to the drug or the associated procedure. UTI rates reported by the authors have been consistently comparable to that related to cystoscopy alone. When CIC is commenced, UTI rates seem to increase to that seen in other CIC patients (<LINK REF="STD-Brubaker-2008" TYPE="STUDY">Brubaker 2008</LINK>).</P>
<P>Other adverse events were uncommon in the included studies, however, as previously stated the studies included small numbers of participants and may have been underpowered to detect rare adverse events. Constipation, transitory aesthenia, dry mouth, and proven chlorhexidine related anaphylaxis were all reported (<LINK REF="STD-Sahai-2005" TYPE="STUDY">Sahai 2005</LINK>). Procedure related adverse events such as pain and haematuria were not specific to botulinum toxin, but also seen in placebo groups.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-11-09 17:30:15 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2011-11-09 17:30:15 +0000" MODIFIED_BY="[Empty name]">
<P>Although the pool of randomised data is still small, they support the efficacy of botulinum toxin in the treatment of OAB. Due to the limited body of data, the issues of long term safety, optimal dose, and best injection technique remain largely unanswered, despite some efforts to explore these issues. There is some suggestion from the data that lower doses may offer comparable efficacy with fewer adverse events, albeit for a shorter duration than higher doses. The duration of effect of botulinum toxin type A may range from three to twelve months. The effect of botulinum toxin type B seems to be limited to less than ten weeks. This may give botulinum toxin type B a role in test-dosing of patients, limiting the duration of adverse effects. In the past injection of the trigone has been avoided to prevent the theoretical risk of ureterovesical reflux. The available evidence suggests, however, that the trigone may be injected without compromising safety or efficacy. Botulinum toxin may be well tolerated without sedation, using only bladder instillation of local anaesthetic. In most studies the risk of UTI seems acceptable. There is further evidence from recent studies that botulinum toxin causes an increase in PVR, and may necessitate the commencement of CIC. Of interest, it appears that patients have an overall improvement in urinary symptom score after botulinum toxin even when it results in the need to initiate CIC. Adequate counselling about the risk of requiring CIC following botulinum toxin should be mandatory. Further, a patient who is unwilling to undertake CIC under any circumstances should not be a candidate for botulinum toxin therapy. The adoption of botulinum toxin as routine practice in many centres still seems largely based on descriptive rather than randomised data. The data presented are based on a patient groups with severe, otherwise treatment refractory OAB, and cautious should be exercised in treating patients with milder symptoms, or those who have not exhausted conventional treatment options.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-10-29 08:37:46 +0100" MODIFIED_BY="[Empty name]">
<P>The studies are still uniformly small, with the largest study examining 77 patients, and have limited follow up. Larger studies with longer follow up would offer more power to identify unusual adverse events. Opportunities still exist for authors to explore optimal dosing, comparison with non-pharmacological treatments, further elucidation of best injection technique, comparing different formulations, and combination with other treatments. Outcomes remain somewhat variable, with some authors still not including quality of life or symptom scores for what is largely a disease of symptoms. Reporting of clinically important parameters of PVR, MDP, and need for CIC has become more common, and these parameters should be included in future studies. Future research would benefit from the creation of a universal criterion for commencing CIC due to elevated PVR. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2011-11-03 15:19:17 +0000" MODIFIED_BY="[Empty name]">
<P>None declared</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-11-03 14:08:48 +0000" MODIFIED_BY="[Empty name]">
<P>For the first version of the review J Duthie, D Wilson, and GP Herbison selected the studies and extracted the data. J Duthie wrote the first draft of the review, and all authors commented on it and suggested changes.</P>
<P>For this update J Duthie and M Vincent selected the studies, extracted the data and wrote the first draft of the review. All authors commented on the review and suggested changes.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-11-08 14:49:05 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2011-11-04 12:46:58 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2011-11-04 11:53:44 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Brubaker-2008" MODIFIED="2010-05-17 10:09:00 +0100" MODIFIED_BY="[Empty name]" NAME="Brubaker 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-17 10:08:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brubaker L, Pelvic Floor Disorders Network (PFDN)</AU>
<TI>Refractory urge urinary incontinence and botulinum A toxin injection (RUBI) trial (Abstract number 2 Oral)</TI>
<SO>Journal of Pelvic Medicine &amp; Surgery</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>5</NO>
<PG>224-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:08:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brubaker L, Pelvic Floor Disorders Network</AU>
<TI>Refractory urge urinary incontinence and botulinum A toxin injection trial (Abstract number 101)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>5</NO>
<PG>728</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:09:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, et al</AU>
<TI>Refractory idiopathic urge urinary incontinence and botulinum A injection</TI>
<SO>Journal of Urology</SO>
<YR>2008</YR>
<VL>180</VL>
<NO>1</NO>
<PG>217-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:07:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brubaker L</AU>
<TI>Refractory urge urinary incontinence and botulinum A injection: The methods of the RUBI trial</TI>
<SO>Journal of Applied Research</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>4</NO>
<PG>260-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ehren-2007" MODIFIED="2010-04-21 09:58:29 +0100" MODIFIED_BY="[Empty name]" NAME="Ehren 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-21 09:58:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C, et al</AU>
<TI>Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity</TI>
<SO>Scandinavian Journal of Urology &amp; Nephrology</SO>
<YR>2007</YR>
<VL>41</VL>
<NO>4</NO>
<PG>335-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Finney-2006" MODIFIED="2011-03-30 07:51:17 +0100" MODIFIED_BY="[Empty name]" NAME="Finney 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-03-30 07:51:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Finney S, Patrick K, Stewart L</AU>
<TI>A double-blind, placebo controlled study investigating efficacy of botulinum toxin type A (Dysport - trademark) in MS related overactive bladder syndrome (OAB): provisional 36 week results (Abstract number 130)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>6</NO>
<PG>663-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flynn-2009" MODIFIED="2011-11-03 11:01:53 +0000" MODIFIED_BY="[Empty name]" NAME="Flynn 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-03-30 07:51:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flynn M, Amundsen C, Webster G</AU>
<TI>Short-term outcomes of a randomized, double-blind placebo controlled trial of botulinum A toxin for the management of severe idiopathic detrusor overactivity incontinence (Abstract number 3 Oral)</TI>
<SO>Journal of Pelvic Medicine &amp; Surgery</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>5</NO>
<PG>225-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-03 11:01:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Flynn M, Amundsen C, Webster G</AU>
<TI>Short-term outcomes of a randomized, double-blind placebo controlled trial of botulinum A toxin for the management of severe idiopathic detrusor overactivity incontinence (Abstract number 317)</TI>
<SO>Proceedings of the 37th Annual Meeting of the International Continence Society (ICS), 20-24 Aug, Rotterdam, the Netherlands</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-03 11:01:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Flynn M, Amundsen C, Webster G</AU>
<TI>Short-term outcomes of a randomized, double-blind placebo controlled trial of botulinum A toxin for the management of severe idiopathic detrusor overactivity incontinence (Abstract number 317)</TI>
<SO>Proceedings of the 37th Annual Meeting of the International Continence Society (ICS), 20-24 Aug, Rotterdam, the Netherlands</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-03 11:01:39 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 19375091&lt;br&gt;IN - Division of Urogynecology, Department of Obstetrics and Gynecology, University of Rochester, Rochester, New York, USA. Michaelk_flynn@urmc.rochester.edu&lt;br&gt;AS - J Urol. 181(6):2608-15, 2009 Jun&lt;br&gt;JC - kc7, 0376374&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, N.I.H., Extramural&lt;br&gt;NO - R21 AG25490-01 (United States NIA NIH HHS)&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2011-11-03 11:01:39 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD</AU>
<TI>Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder</TI>
<SO>Journal of Urology</SO>
<YR>2009</YR>
<VL>181</VL>
<NO>6</NO>
<PG>2608-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghei-2005" MODIFIED="2010-05-17 10:32:31 +0100" MODIFIED_BY="[Empty name]" NAME="Ghei 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghei M, Maraj B, Miller R, Nathan S, O'Sullivan C, Fowler CJ, et al</AU>
<TI>Effects of botulinum toxin B on refractory detrusor overactivity: a randomised, double blind, placebo controlled, crossover trial</TI>
<SO>The Journal of Urology</SO>
<YR>2005</YR>
<VL>174</VL>
<NO>5</NO>
<PG>972-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:32:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghei M, Maraj BH, Miller R, Nathan S, O'Sullivan C, Fowler CJ, et al</AU>
<TI>Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial</TI>
<SO>Journal of Urology</SO>
<YR>2005</YR>
<VL>174</VL>
<NO>5</NO>
<PG>1873-1877; discussion 1877</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giannantoni-2004" MODIFIED="2008-10-28 12:01:27 +0000" MODIFIED_BY="[Empty name]" NAME="Giannantoni 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-28 12:01:27 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M</AU>
<TI>Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomised study</TI>
<SO>The Journal of Urology</SO>
<YR>2004</YR>
<VL>172</VL>
<NO>1</NO>
<PG>240-3</PG>
<IDENTIFIERS MODIFIED="2008-10-28 12:01:27 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 12:01:27 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="19320"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gousse-2005" MODIFIED="2011-11-04 11:53:44 +0000" MODIFIED_BY="[Empty name]" NAME="Gousse 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-11-03 10:57:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Caruso D, Kanagarajah P, Gousse A</AU>
<TI>100 vs. 150 units of intra-detrusor Botox (trademark): dose differences in OAB-wet patients? (Abstract number 316)</TI>
<SO>Proceedings of the 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 - Oct 3, San Francisco, CA</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:13:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen BL, Barboglio P, Rodriguez D, Gousse AE</AU>
<TI>Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>3</NO>
<PG>205-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-04 11:53:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen BL, Rivera R, Barboglio P, Gousse A</AU>
<TI>Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection</TI>
<SO>Journal of Urology</SO>
<YR>2007</YR>
<VL>177</VL>
<NO>3</NO>
<PG>1006-10; discussion 1010</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:27:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gousse A, Barboglio P, Cohen B, Rodriguez D, Caruso D</AU>
<TI>Botox (R) for idiopathic overactive bladder patients refractory to antimuscarinic therapy in the absence of detrusor overactivity (Abstract number 133)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>7</NO>
<PG>724-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-03 10:58:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gousse A, Barboglio P, Cohen B, Rodriguez D, Caruso D</AU>
<TI>Can we predict who will respond to botulinum toxin-A injections for idiopathic overactive bladder? (Abstract number 538)</TI>
<SO>Proceedings of the 38th Annual Meeting of the International Continence Society (ICS), 20-24 Oct, Cairo, Egypt</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-03 10:58:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gousse A, Barboglio P, Cohen B, Rodriguez D, Caruso D</AU>
<TI>The need for intermittent catheterization during repeated Botox (trademark) injections for idiopathic OAB (Abstract number 417)</TI>
<SO>Proceedings of the 38th Annual Meeting of the International Continence Society (ICS), 20-24 Oct, Cairo, Egypt</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:23:49 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gousse A, Cohen B, Rodriguez D, Barboglio P</AU>
<TI>Botulinum toxin A 100 vs 150 units in idiopathic overactive bladder patients: is there any difference? (Abstract number 100)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>5</NO>
<PG>726-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:23:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gousse A, Cohen B, Rodriguez D, Barboglio P</AU>
<TI>Botulinum toxin A: intradetrusor re-injections in idiopathic overactive bladder every 6 months - 3 years follow up (Abstract number 102)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>5</NO>
<PG>728-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:24:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gousse A, Rivera R, Tunuguntla H, Barboglio P</AU>
<TI>Repeated intradetrusor injections of botulinum toxin-A in neurogenic overactive bladder: urodynamic, UDI-6 and quality of life data (Abstract number 103)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>5</NO>
<PG>730-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:27:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gousse A, Shirodkar S, Gomez C, Kanagarajah P, Barboglio P, Caruso D</AU>
<TI>Botox (trademark) for idiopathic overactive bladder patients refractory to antimuscarinic therapy in the absence of urodynamically demonstrable detrusor overactivity (Abstract number: Poster# 64)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>2</NO>
<PG>144-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:11:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Gousse A, Tunuguntla H, Rodriguez D, Velasquez D</AU>
<TI>Dose-finding prospective randomised study to evaluate the efficacy and safety of botulinum-A toxin of refractory idiopathic overactive bladder (Abstract number 254)</TI>
<SO>Proceedings of the 35th Annual Meeting of the International Continence Society (ICS); 2005 Aug 28 - Sept 2; Montreal</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2008-10-28 12:01:08 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 12:01:08 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="21069"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:22:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gousse AE, Barboglio P, Rivera R, Tunuguntla H, Cason L</AU>
<TI>Repeat Botox A injections and urodynamic findings in neurogenic OAB: long-tem results (Abstract number 20)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>7 Suppl</NO>
<PG>1071</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:22:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gousse AE, Cohen B, Rodriguez D, Barboglio PG</AU>
<TI>Scheduled repeated Botox (trademark) injections for idiopathic OAB: evaluating therapeutic time (Poster abstract number 1192)</TI>
<SO>Journal of Urology</SO>
<YR>2007</YR>
<VL>177</VL>
<NO>4 Suppl S</NO>
<PG>39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:21:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gousse AE, Tununguntia HSGR, Bateman D, Velasquez D</AU>
<TI>Dose-finding prospective randomized study to evaluate the efficacy and safety of botulinum-A toxin for refractory non-neurogenic overactive bladder (Abstract)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>2</NO>
<PG>161</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grise-2008" MODIFIED="2011-11-03 10:55:10 +0000" MODIFIED_BY="[Empty name]" NAME="Grise 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-11-03 10:55:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Grise P, Ruffion A, Chartier-Kastler E, Denys P, Egon G</AU>
<TI>Impact on continence of only bladder botulinum toxin injection without antimuscarinics in neurogenic patients (Abstract number 356)</TI>
<SO>Proceedings of the 38th Annual Meeting of the International Continence Society (ICS), 20-24 Oct, Cairo, Egypt</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herschorn-2009" MODIFIED="2010-05-17 10:34:02 +0100" MODIFIED_BY="[Empty name]" NAME="Herschorn 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-17 10:34:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al</AU>
<TI>Botulinum toxin A in patients with neurogenic detrusor overactivity: preliminary results from a Canadian multicentre randomized trial (Abstract number: Poster# 50)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>2</NO>
<PG>138-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-21 10:00:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al</AU>
<TI>Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence - a randomized double-blind trial (Abstract number 33)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>7</NO>
<PG>608-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karsenty-2005" MODIFIED="2008-10-28 12:01:35 +0000" MODIFIED_BY="[Empty name]" NAME="Karsenty 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-10-28 12:01:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karsenty G, Boy S, Reitz A, et al</AU>
<TI>Botulinum toxin-A (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI)-a prospective randomized study to compare 30 vs. 10 injection sites (abstract)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>5/6</NO>
<PG>547-8</PG>
<IDENTIFIERS MODIFIED="2008-10-28 12:01:35 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 12:01:35 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="20977"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-King-2007" MODIFIED="2010-04-21 10:00:36 +0100" MODIFIED_BY="[Empty name]" NAME="King 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-21 10:00:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>King J, Neville J</AU>
<TI>A randomised, double-blind, placebo-controlled trial of botulinum toxin type A injections for the treatment of refractory idiopathic detrusor overactivity</TI>
<SO>International Urogynecology Journal &amp; Pelvic Floor Dysfunction</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>Suppl 1</NO>
<PG>S77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuo-2006" MODIFIED="2011-11-03 10:59:23 +0000" MODIFIED_BY="[Empty name]" NAME="Kuo 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-11-03 10:59:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kuo H, Liu H</AU>
<TI>Will suburothelial injection of different dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? (Abstract number 145)</TI>
<SO>Proceedings of the 36th Annual Meeting of the ICS, 2006, 27 Nov-1 Dec, Christchurch, New Zealand</SO>
<YR>2006</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:36:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuo HC</AU>
<TI>Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?</TI>
<SO>Urology</SO>
<YR>2006</YR>
<VL>68</VL>
<NO>5</NO>
<PG>993-997, discussion 997-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuo-2007" MODIFIED="2010-05-17 10:38:29 +0100" MODIFIED_BY="[Empty name]" NAME="Kuo 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-21 10:00:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuo H-C</AU>
<TI>Comparative study of the therapeutic effects of different intravesical injections of botulinum toxin A on overactive bladder (Poster abstract number 1190)</TI>
<SO>Journal of Urology</SO>
<YR>2007</YR>
<VL>177</VL>
<NO>4 Suppl S</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:38:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuo HC</AU>
<TI>Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity</TI>
<SO>Journal of Urology</SO>
<YR>2007</YR>
<VL>178</VL>
<NO>4 Pt 1</NO>
<PG>1359-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lucioni-2008" MODIFIED="2010-04-21 10:01:10 +0100" MODIFIED_BY="[Empty name]" NAME="Lucioni 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-04-21 10:01:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lucioni A, Rapp DE, Reynolds WS, Gong EM, Fedunok PA, Bales GT</AU>
<TI>Evaluation of the effect of injection volumes of intravesical botulinum-A toxin injections in patients with overactive bladder symptoms (Abstract number 17)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>2</NO>
<PG>132</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moore-2009" MODIFIED="2010-04-21 10:01:21 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-04-21 10:01:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore KM, Hirst G, Emery S, Turner A, Lucas M</AU>
<TI>A double blind, placebo controlled, randomised, cross over study of trigone specific injections of botulinum toxin B for treating patients with idiopathic detrusor overactivity refractory to other conservative treatments (Abstract number 209)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>7</NO>
<PG>833-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sahai-2005" MODIFIED="2011-11-03 11:00:02 +0000" MODIFIED_BY="[Empty name]" NAME="Sahai 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-11-03 11:00:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sahai A, Dowson C, Khan MS, Dasgupta P</AU>
<TI>Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial</TI>
<SO>BJU International</SO>
<YR>2009</YR>
<VL>103</VL>
<NO>11</NO>
<PG>1509-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-28 12:01:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Sahai A, Khan M, Smith K, Dasgupta P</AU>
<TI>Botulinum toxin-A for patients with idiopathic detrusor overactivity: early results from a randomised, double-blind, placebo-controlled trial</TI>
<SO>Proceedings of the 35th Annual International Continence Society (ICS); 2005 Aug 28 - Sept 2; Montreal</SO>
<YR>2005</YR>
<PG>Abstract 428</PG>
<IDENTIFIERS MODIFIED="2008-10-28 12:01:44 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 12:01:44 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="21092"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:40:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sahai A, Khan MS, Dasgupta P</AU>
<TI>Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial</TI>
<SO>Journal of Urology</SO>
<YR>2007</YR>
<VL>177</VL>
<NO>6</NO>
<PG>2231-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:39:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sahai A, Khan S, Dasgupta P</AU>
<TI>Quality of life in patients with symptoms of overactive bladder and refractory idiopathic detrusor over activity following intradetrusor injections of botulinum toxin type A: results from a randomised, double blind, placebo-controlled trial (Abstract number 675)</TI>
<SO>European Urology Supplements</SO>
<YR>2006</YR>
<VL>5</VL>
<PG>191</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schurch-2005" MODIFIED="2011-03-30 07:52:06 +0100" MODIFIED_BY="[Empty name]" NAME="Schurch 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-03-30 07:52:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schurch B, De Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al</AU>
<TI>Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomised, placebo controlled 6-month study</TI>
<SO>The Journal of Urology</SO>
<YR>2005</YR>
<VL>174</VL>
<NO>1</NO>
<PG>196-200</PG>
<IDENTIFIERS MODIFIED="2008-10-28 12:01:53 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 12:01:53 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="20654"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:42:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schurch B, De Seze M, Denys P, Chartier-Kastler E, Haab F, Evereart K et al</AU>
<TI>Subgroup analysis to determine impact of patient demographics on urodynamic response to focal administration of botulinum toxin A</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>5/6</NO>
<PG>545-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:43:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron RL</AU>
<TI>Botulinum toxin a improves the quality of life of patients with neurogenic urinary incontinence</TI>
<SO>European Urology</SO>
<YR>2007</YR>
<VL>52</VL>
<NO>3</NO>
<PG>850-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-17 10:43:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schurch B</AU>
<TI>Botulinum toxin in the treatment of neurogenic bladder in adults and children</TI>
<SO>European Urology, Supplements</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>11</NO>
<PG>679-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thavaseelan-2005" MODIFIED="2008-10-28 12:02:00 +0000" MODIFIED_BY="[Empty name]" NAME="Thavaseelan 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-10-28 12:02:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thavaseelan J T, Burns-Cox N, Jordan K, Trewhella J</AU>
<TI>Efficacy of botulinum toxin type A (BOTOX) in the management of the neurogenic bladder: a prospective, randomised, double blind, dose comparative trial - interim overview of results</TI>
<SO>British Journal of Urology</SO>
<YR>2005</YR>
<VL>95 Suppl 1</VL>
<PG>4-5</PG>
<IDENTIFIERS MODIFIED="2008-10-28 12:02:00 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 12:02:00 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="21155"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Truzzi-2004" MODIFIED="2008-10-28 12:02:07 +0000" MODIFIED_BY="[Empty name]" NAME="Truzzi 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-28 12:02:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Truzzi J, Bruschini H, Simonetti R, Miguel S</AU>
<TI>What is the best dose for intravesical botulinum-A toxin injected in overactive bladder treatment? A prospective randomised preliminary study</TI>
<SO>Proceedings of the International Continence Society (34th Annual Meeting), and the International Urogynaecological Association; 2004 Aug 23-27; Paris</SO>
<YR>2004</YR>
<PG>Abstract 520</PG>
<IDENTIFIERS MODIFIED="2008-10-28 12:02:07 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 12:02:07 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="19069"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-11-04 12:46:58 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Brubaker-2006" MODIFIED="2010-05-17 10:06:07 +0100" MODIFIED_BY="[Empty name]" NAME="Brubaker 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-17 10:06:07 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - CCTR&lt;br&gt;AN - CN-00641808 NEW&lt;br&gt;PT - Journal: Article&lt;/p&gt;" NOTES_MODIFIED="2010-05-17 10:06:07 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brubaker L</AU>
<TI>Refractory urge urinary incontinence and botulinum A injection: The methods of the RUBI trial</TI>
<SO>Journal of Applied Research</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>4</NO>
<PG>260-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brubaker-2007" MODIFIED="2010-05-17 10:07:39 +0100" MODIFIED_BY="[Empty name]" NAME="Brubaker 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-05-17 10:07:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brubaker L, Pelvic Floor Disorders Network (PFDN)</AU>
<TI>Refractory urge urinary incontinence and botulinum A toxin injection (RUBI) trial (Abstract number 2 Oral)</TI>
<SO>Journal of Pelvic Medicine &amp; Surgery</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>5</NO>
<PG>224-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brubaker-2007a" MODIFIED="2010-05-17 10:08:20 +0100" MODIFIED_BY="[Empty name]" NAME="Brubaker 2007a" YEAR="2007">
<REFERENCE MODIFIED="2010-05-17 10:08:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brubaker L, Pelvic Floor Disorders Network</AU>
<TI>Refractory urge urinary incontinence and botulinum A toxin injection trial (Abstract number 101)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>5</NO>
<PG>728</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caruso-2009" MODIFIED="2010-05-26 07:52:10 +0100" MODIFIED_BY="[Empty name]" NAME="Caruso 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-26 07:52:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Caruso D, Kanagarajah P, Gousse A</AU>
<TI>100 vs. 150 units of intra-detrusor Botox (trademark): dose differences in OAB-wet patients? (Abstract number 316)</TI>
<SO>Proceedings of the 39th Annual Meeting of the International Continence Society (ICS), 2009 Sep 29 - Oct 3, San Francisco, CA</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2007" MODIFIED="2010-05-17 10:10:26 +0100" MODIFIED_BY="[Empty name]" NAME="Cohen 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-05-17 10:10:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen BL, Rivera R, Barboglio P, Gousse A</AU>
<TI>Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection</TI>
<SO>Journal of Urology</SO>
<YR>2007</YR>
<VL>177</VL>
<NO>3</NO>
<PG>1006-1010; discussion 1010</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2008" MODIFIED="2010-05-17 10:12:03 +0100" MODIFIED_BY="[Empty name]" NAME="Cohen 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-05-17 10:12:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen BL, Barboglio P, Gousse AE</AU>
<TI>Can we predict who will respond to botulinum toxin-A injections for idiopathic overactive bladder? (Abstract number 18)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>2</NO>
<PG>132-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2009" MODIFIED="2010-05-17 10:13:21 +0100" MODIFIED_BY="[Empty name]" NAME="Cohen 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-17 10:13:21 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 19058190&lt;br&gt;IN - Department of Urology, Division of Female Urology, Voiding Dysfunction &amp;amp; Reconstructive Urology, University of Miami, Miller School of Medicine, Miami, Florida 33101, USA&lt;br&gt;AS - Neurourol Urodyn. 28(3):205-8, 2009&lt;br&gt;JC - brq, 8303326&lt;br&gt;SB - IM&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-05-17 10:13:21 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen BL, Barboglio P, Rodriguez D, Gousse AE</AU>
<TI>Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>3</NO>
<PG>205-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2009a" MODIFIED="2011-11-04 12:46:58 +0000" MODIFIED_BY="[Empty name]" NAME="Cohen 2009a" YEAR="2009">
<REFERENCE MODIFIED="2011-11-04 12:46:58 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 19746201&lt;br&gt;IN - Department of Urology, University of Miami Miller School of Medicine, Miami, FL 33101, USA&lt;br&gt;AS - Adv. urol.. :328364, 2009&lt;br&gt;JC - 101476240&lt;br&gt;CP - Egypt&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2011-11-04 12:46:58 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen BL, Caruso DJ, Kanagarajah P, Gousse AE</AU>
<TI>Predictors of response to intradetrusor botulinum toxin-a injections in patients with idiopathic overactive bladder</TI>
<SO>Advances in Urology</SO>
<YR>2009</YR>
<VL>2009</VL>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cui-2007" MODIFIED="2011-11-04 12:32:08 +0000" MODIFIED_BY="[Empty name]" NAME="Cui 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-11-04 12:32:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cui X-G, Qu C-Y, Xu D-F, Ren J-Z, Kong L-L, Lin H-Y</AU>
<TI>Botulinum toxin injection into urethral external sphincter combined with oral baclofen in treatment of patients with detrusor-external sphincter dyssynergia after spinal cord injury</TI>
<SO>Academic Journal of Second Military Medical University</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>8</NO>
<PG>875-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Seze-2002" MODIFIED="2011-03-30 07:52:39 +0100" MODIFIED_BY="[Empty name]" NAME="de Seze 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-03-30 07:52:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Seze M, Petit H, Gallien P, de Seze MP, Joseph PA, Mazaux JM, Barat M</AU>
<TI>Botulinum A toxin and detrusor dyssynergia: A double-blind lidocaine-controlled study in 13 patients with spinal cord disease</TI>
<SO>European Urology</SO>
<YR>2002</YR>
<VL>42</VL>
<NO>1</NO>
<PG>56-62</PG>
<IDENTIFIERS MODIFIED="2008-10-28 12:02:40 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 12:02:40 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="15931"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dykstra-1990" MODIFIED="2008-10-28 12:02:46 +0000" MODIFIED_BY="[Empty name]" NAME="Dykstra 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-10-28 12:02:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dykstra DD, Sidi AA</AU>
<TI>Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1990</YR>
<VL>71</VL>
<NO>1</NO>
<PG>24-6</PG>
<IDENTIFIERS MODIFIED="2008-10-28 12:02:46 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 12:02:46 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="384"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farid-2009" MODIFIED="2010-04-21 09:53:50 +0100" MODIFIED_BY="[Empty name]" NAME="Farid 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-04-21 09:53:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farid M, Youssef T, Mahdy T, Omar W, Moneim HA, El Nakeeb A, et al</AU>
<TI>Comparative study between botulinum toxin injection and partial division of puborectalis for treating anismus</TI>
<SO>International Journal of Colorectal Disease</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>3</NO>
<PG>327-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farid-2009a" MODIFIED="2010-04-21 09:53:56 +0100" MODIFIED_BY="[Empty name]" NAME="Farid 2009a" YEAR="2009">
<REFERENCE MODIFIED="2010-04-21 09:53:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farid M, El Monem HA, Omar W, El Nakeeb A, Fikry A, Youssef T, et al</AU>
<TI>Comparative study between biofeedback retraining and botulinum neurotoxin in the treatment of anismus patients</TI>
<SO>International Journal of Colorectal Disease</SO>
<YR>2009</YR>
<VL>24</VL>
<NO>1</NO>
<PG>115-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flynn-2007" MODIFIED="2011-03-30 07:52:54 +0100" MODIFIED_BY="[Empty name]" NAME="Flynn 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-03-30 07:52:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flynn M, Amundsen C, Webster G</AU>
<TI>Short-term outcomes of a randomized, double-blind placebo controlled trial of botulinum A toxin for the management of severe idiopathic detrusor overactivity incontinence (Abstract number 3 Oral)</TI>
<SO>Journal of Pelvic Medicine &amp; Surgery</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>5</NO>
<PG>225-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flynn-2007a" MODIFIED="2011-11-04 11:54:43 +0000" MODIFIED_BY="[Empty name]" NAME="Flynn 2007a" YEAR="2007">
<REFERENCE MODIFIED="2011-11-04 11:54:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Flynn M, Amundsen C, Webster G</AU>
<TI>Short-term outcomes of a randomized, double-blind placebo controlled trial of botulinum A toxin for the management of severe idiopathic detrusor overactivity incontinence (Abstract number 317)</TI>
<SO>Proceedings of the 37th Annual Meeting of the International Continence Society (ICS), 20-24 Aug, Rotterdam, The Netherlands</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flynn-2008" MODIFIED="2010-04-21 10:04:21 +0100" MODIFIED_BY="[Empty name]" NAME="Flynn 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-04-21 10:04:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flynn M, Amundsen C, Perevich M, Webster G</AU>
<TI>Short-term outcomes of a randomized, double-blind placebo controlled trial of botulinum A toxin for the management of severe idiopathic detrusor overactivity incontinence (Abstract number 33, poster)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>2</NO>
<PG>151-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallien-2005" MODIFIED="2010-04-21 09:54:16 +0100" MODIFIED_BY="[Empty name]" NAME="Gallien 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-04-21 09:54:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallien P, Reymann JM, Amarenco G, Nicolas B, de Seze M, Bellissant E</AU>
<TI>Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>2005</YR>
<VL>76</VL>
<NO>12</NO>
<PG>1670-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghei-2005a" MODIFIED="2010-05-17 10:32:10 +0100" MODIFIED_BY="[Empty name]" NAME="Ghei 2005a" YEAR="2005">
<REFERENCE MODIFIED="2010-05-17 10:32:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghei M, Maraj BH, Miller R, Nathan S, O'Sullivan C, Fowler CJ, et al</AU>
<TI>Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial</TI>
<SO>Journal of Urology</SO>
<YR>2005</YR>
<VL>174</VL>
<NO>5</NO>
<PG>1873-1877; discussion 1877</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghei-2006" MODIFIED="2010-04-21 09:54:31 +0100" MODIFIED_BY="[Empty name]" NAME="Ghei 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-04-21 09:54:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghei M, Maraj BH, Nathan S, Malone-Lee J, Miller R</AU>
<TI>Autonomic side effects of Botulinum toxin Type B Intravesical injections: Report of 4 cases and review of the literature</TI>
<SO>International Urology &amp; Nephrology</SO>
<YR>2006</YR>
<VL>38</VL>
<NO>3-4</NO>
<PG>543-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giannantoni-2003" MODIFIED="2008-10-28 12:02:53 +0000" MODIFIED_BY="[Empty name]" NAME="Giannantoni 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-10-28 12:02:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giannantoni A, Di Stasi SM, Pizzirusso G, Mearini E, Bini V, Porena M</AU>
<TI>Intravesical resiniferatoxin versus botulinum-A toxin injections for the treatment of neurogenic detrusor overactivity (Abstract)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2003</YR>
<VL>22</VL>
<NO>5</NO>
<PG>497</PG>
<IDENTIFIERS MODIFIED="2008-10-28 12:02:53 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 12:02:53 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="17103"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giannantoni-2004B" MODIFIED="2008-10-28 12:03:01 +0000" MODIFIED_BY="[Empty name]" NAME="Giannantoni 2004B" YEAR="2004">
<REFERENCE MODIFIED="2008-10-28 12:03:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giannantoni A, Mearini E, Di Stasi SM, Constantini E, Zucchi A, Mearini L, et al</AU>
<TI>New therapeutic options for refractory detrusor overactivity</TI>
<SO>Minerva Urologica e Nefrologica</SO>
<YR>2004</YR>
<VL>56</VL>
<NO>1</NO>
<PG>79-87</PG>
<IDENTIFIERS MODIFIED="2008-10-28 12:03:01 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 12:03:01 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="20255"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gousse-2005-B" MODIFIED="2008-10-28 12:03:36 +0000" MODIFIED_BY="[Empty name]" NAME="Gousse 2005 B" YEAR="2005">
<REFERENCE MODIFIED="2008-10-28 12:03:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gousse A, Tunuguntla H, Rodriguez D, Velasquez D</AU>
<TI>Validated instrument to assess pain tolerance during flexible endoscopy for intradetrusor botox-A injection (Abstract number 520)</TI>
<SO>Proceedings of the 35th Annual International Continence Society (ICS); 2005 Aug 28 - Sept 2; Montreal</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2008-10-28 12:03:36 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 12:03:36 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="21070"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gousse-2005a" MODIFIED="2010-05-17 10:20:53 +0100" MODIFIED_BY="[Empty name]" NAME="Gousse 2005a" YEAR="2005">
<REFERENCE MODIFIED="2010-05-17 10:20:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gousse AE, Tununguntia HSGR, Bateman D, Velasquez D</AU>
<TI>Dose-finding prospective randomized study to evaluate the efficacy and safety of botulinum-A toxin for refractory non-neurogenic overactive bladder (Abstract)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>2</NO>
<PG>161</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gousse-2007" MODIFIED="2010-05-17 10:21:38 +0100" MODIFIED_BY="[Empty name]" NAME="Gousse 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-05-17 10:21:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gousse AE, Cohen B, Rodriguez D, Barboglio PG</AU>
<TI>Scheduled repeated Botox (trademark) injections for idiopathic OAB: evaluating therapeutic time (Poster abstract number 1192)</TI>
<SO>Journal of Urology</SO>
<YR>2007</YR>
<VL>177</VL>
<NO>4 Suppl S</NO>
<PG>39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gousse-2007a" MODIFIED="2010-05-17 10:22:20 +0100" MODIFIED_BY="[Empty name]" NAME="Gousse 2007a" YEAR="2007">
<REFERENCE MODIFIED="2010-05-17 10:22:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gousse AE, Barboglio P, Rivera R, Tunuguntla H, Cason L</AU>
<TI>Repeat Botox A injections and urodynamic findings in neurogenic OAB: long-tem results (Abstract number 20)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>7 Suppl</NO>
<PG>1071</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gousse-2007b" MODIFIED="2010-05-17 10:23:00 +0100" MODIFIED_BY="[Empty name]" NAME="Gousse 2007b" YEAR="2007">
<REFERENCE MODIFIED="2010-05-17 10:23:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gousse A, Cohen B, Rodriguez D, Barboglio P</AU>
<TI>Botulinum toxin A: intradetrusor re-injections in idiopathic overactive bladder every 6 months - 3 years follow up (Abstract number 102)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>5</NO>
<PG>728-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gousse-2007c" MODIFIED="2010-05-17 10:23:29 +0100" MODIFIED_BY="[Empty name]" NAME="Gousse 2007c" YEAR="2007">
<REFERENCE MODIFIED="2010-05-17 10:23:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gousse A, Cohen B, Rodriguez D, Barboglio P</AU>
<TI>Botulinum toxin A 100 vs 150 units in idiopathic overactive bladder patients: is there any difference? (Abstract number 100)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>5</NO>
<PG>726-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gousse-2007d" MODIFIED="2010-05-17 10:24:07 +0100" MODIFIED_BY="[Empty name]" NAME="Gousse 2007d" YEAR="2007">
<REFERENCE MODIFIED="2010-05-17 10:24:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gousse A, Rivera R, Tunuguntla H, Barboglio P</AU>
<TI>Repeated intradetrusor injections of botulinum toxin-A in neurogenic overactive bladder: urodynamic, UDI-6 and quality of life data (Abstract number 103)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>5</NO>
<PG>730-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gousse-2008" MODIFIED="2011-11-03 11:02:22 +0000" MODIFIED_BY="[Empty name]" NAME="Gousse 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-11-03 11:02:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gousse A, Barboglio P, Cohen B, Rodriguez D, Caruso D</AU>
<TI>The need for intermittent catheterization during repeated Botox (trademark) injections for idiopathic OAB (Abstract number 417)</TI>
<SO>Proceedings of the 38th Annual Meeting of the International Continence Society (ICS), 20-24 Oct, Cairo, Egypt</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gousse-2008a" MODIFIED="2011-11-03 11:02:36 +0000" MODIFIED_BY="[Empty name]" NAME="Gousse 2008a" YEAR="2008">
<REFERENCE MODIFIED="2011-11-03 11:02:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Gousse A, Barboglio P, Cohen B, Rodriguez D, Caruso D</AU>
<TI>Can we predict who will respond to botulinum toxin-A injections for idiopathic overactive bladder? (Abstract number 538)</TI>
<SO>Proceedings of the 38th Annual Meeting of the International Continence Society (ICS), 20-24 Oct, Cairo, Egypt</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gousse-2008b" MODIFIED="2010-05-17 10:26:41 +0100" MODIFIED_BY="[Empty name]" NAME="Gousse 2008b" YEAR="2008">
<REFERENCE MODIFIED="2010-05-17 10:26:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gousse A, Barboglio P, Cohen B, Rodriguez D, Caruso D</AU>
<TI>Botox (R) for idiopathic overactive bladder patients refractory to antimuscarinic therapy in the absence of detrusor overactivity (Abstract number 133)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>7</NO>
<PG>724-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gousse-2009" MODIFIED="2010-05-17 10:27:20 +0100" MODIFIED_BY="[Empty name]" NAME="Gousse 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-05-17 10:27:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gousse A, Shirodkar S, Gomez C, Kanagarajah P, Barboglio P, Caruso D</AU>
<TI>Botox (trademark) for idiopathic overactive bladder patients refractory to antimuscarinic therapy in the absence of urodynamically demonstrable detrusor overactivity (Abstract number: Poster# 64)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>2</NO>
<PG>144-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herschorn-2009a" MODIFIED="2010-05-17 10:33:35 +0100" MODIFIED_BY="[Empty name]" NAME="Herschorn 2009a" YEAR="2009">
<REFERENCE MODIFIED="2010-05-17 10:33:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al</AU>
<TI>Botulinum toxin A in patients with neurogenic detrusor overactivity: preliminary results from a Canadian multicentre randomized trial (Abstract number: Poster# 50)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>2</NO>
<PG>138-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keshtgar-2007" MODIFIED="2010-04-21 09:55:01 +0100" MODIFIED_BY="[Empty name]" NAME="Keshtgar 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-21 09:55:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keshtgar AS, Ward HC, Sanei A, Clayden GS</AU>
<TI>Botulinum toxin, a new treatment modality for chronic idiopathic constipation in children: long-term follow-up of a double-blind randomized trial</TI>
<SO>Journal of Pediatric Surgery</SO>
<YR>2007</YR>
<VL>42</VL>
<NO>4</NO>
<PG>672-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kessler-2007" MODIFIED="2010-04-21 09:55:12 +0100" MODIFIED_BY="[Empty name]" NAME="Kessler 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-21 09:55:12 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 18074438&lt;br&gt;IN - Department of Urology, University of Bern, 3010 Bern, Switzerland. tkessler@gmx.ch&lt;br&gt;AS - Eur Urol. 52(6):1793-4, 2007 Dec&lt;br&gt;JC - enm, 7512719&lt;br&gt;SB - IM&lt;br&gt;CP - Switzerland&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2010-04-21 09:55:12 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kessler TM</AU>
<TI>Words of wisdom. Re: Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial</TI>
<SO>European Urology</SO>
<YR>2007</YR>
<VL>52</VL>
<NO>6</NO>
<PG>1793-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuo-2006a" MODIFIED="2010-05-17 10:36:14 +0100" MODIFIED_BY="[Empty name]" NAME="Kuo 2006a" YEAR="2006">
<REFERENCE MODIFIED="2010-05-17 10:36:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuo HC</AU>
<TI>Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity?</TI>
<SO>Urology</SO>
<YR>2006</YR>
<VL>68</VL>
<NO>5</NO>
<PG>993-997, discussion 997-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuo-2007a" MODIFIED="2010-04-21 09:55:50 +0100" MODIFIED_BY="[Empty name]" NAME="Kuo 2007a" YEAR="2007">
<REFERENCE MODIFIED="2010-04-21 09:55:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuo H-C</AU>
<TI>Comparison of the therapeutic effects of urethral injections of 50 and 100 units of botulinum A toxin for voiding dysfunction</TI>
<SO>Tzu Chi Medical Journal</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>3</NO>
<PG>134-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuo-2007b" MODIFIED="2010-04-21 09:56:01 +0100" MODIFIED_BY="[Empty name]" NAME="Kuo 2007b" YEAR="2007">
<REFERENCE MODIFIED="2010-04-21 09:56:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuo HC</AU>
<TI>Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction</TI>
<SO>Urology</SO>
<YR>2007</YR>
<VL>69</VL>
<NO>1</NO>
<PG>57-61, discussion 61-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuo-2007c" MODIFIED="2010-05-17 10:37:59 +0100" MODIFIED_BY="[Empty name]" NAME="Kuo 2007c" YEAR="2007">
<REFERENCE MODIFIED="2010-05-17 10:37:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuo HC</AU>
<TI>Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity</TI>
<SO>Journal of Urology</SO>
<YR>2007</YR>
<VL>178</VL>
<NO>4 Pt 1</NO>
<PG>1359-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maria-1998" MODIFIED="2008-10-28 12:03:45 +0000" MODIFIED_BY="[Empty name]" NAME="Maria 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-10-28 12:03:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maria G, Cassetta E, Gui D, Brisinda G, Bentivoglio AR, Albanese A</AU>
<TI>A comparison of botulinum toxin and saline for the treatment of chronic anal fissure</TI>
<SO>New England Journal of Medicine</SO>
<YR>1998</YR>
<VL>338</VL>
<PG>217-20</PG>
<IDENTIFIERS MODIFIED="2008-10-28 12:03:45 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 12:03:45 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="5285"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maria-2003" MODIFIED="2008-10-28 12:03:52 +0000" MODIFIED_BY="[Empty name]" NAME="Maria 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-10-28 12:03:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A</AU>
<TI>Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study</TI>
<SO>Urology</SO>
<YR>2003</YR>
<VL>62</VL>
<NO>2</NO>
<PG>259-64</PG>
<IDENTIFIERS MODIFIED="2008-10-28 12:03:52 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 12:03:52 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="16639"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neel-2007" MODIFIED="2010-04-21 09:56:48 +0100" MODIFIED_BY="[Empty name]" NAME="Neel 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-21 09:56:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neel KF, Soliman S, Salem M, Seida M, Al Hazmi H, Khatab A</AU>
<TI>Botulinum-A toxin: solo treatment for neuropathic noncompliant bladder</TI>
<SO>Journal of Urology</SO>
<YR>2007</YR>
<VL>178</VL>
<NO>6</NO>
<PG>2593-2597; discussion 2597-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ron-2001" NAME="Ron 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ron Y, Avni Y, Lukovetski A, Wardi J, Geva D, Birkenfeld S, Halpern Z</AU>
<TI>Botulinum toxin type-a in therapy of patients with anismus</TI>
<SO>Diseases of the Colon &amp; Rectum</SO>
<YR>2001</YR>
<VL>44</VL>
<NO>12</NO>
<PG>1821-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="12862"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sahai-2006" MODIFIED="2010-05-17 10:39:41 +0100" MODIFIED_BY="[Empty name]" NAME="Sahai 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-17 10:39:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sahai A, Khan S, Dasgupta P</AU>
<TI>Quality of life in patients with symptoms of overactive bladder and refractory idiopathic detrusor over activity following intradetrusor injections of botulinum toxin type A: results from a randomised, double blind, placebo-controlled trial (Abstract number 675)</TI>
<SO>European Urology Supplements</SO>
<YR>2006</YR>
<VL>5</VL>
<PG>191</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sahai-2007" MODIFIED="2010-05-17 10:40:25 +0100" MODIFIED_BY="[Empty name]" NAME="Sahai 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-05-17 10:40:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sahai A, Khan MS, Dasgupta P</AU>
<TI>Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial</TI>
<SO>Journal of Urology</SO>
<YR>2007</YR>
<VL>177</VL>
<NO>6</NO>
<PG>2231-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sahai-2009" MODIFIED="2011-11-03 11:55:46 +0000" MODIFIED_BY="[Empty name]" NAME="Sahai 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-11-03 11:55:46 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 19389019&lt;br&gt;IN - Department of Urology Guy's Hospital and King's College London School of Medicine, London, UK&lt;br&gt;AS - BJU Int. 103(11):1509-15, 2009 Jun&lt;br&gt;JC - dcu, 100886721&lt;br&gt;SB - IM&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2011-11-03 11:55:46 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sahai A, Dowson C, Khan MS, Dasgupta P</AU>
<TI>Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial</TI>
<SO>BJU International</SO>
<YR>2009</YR>
<VL>103</VL>
<NO>11</NO>
<PG>1509-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schurch-2004" MODIFIED="2008-10-28 12:04:00 +0000" MODIFIED_BY="[Empty name]" NAME="Schurch 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-28 12:04:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schurch B, Reitz A, Tenti G</AU>
<TI>Electromotive drug administration of lidocaine to anaesthetise the bladder before botulinum-A toxin injections into the detrusor</TI>
<SO>Spinal Cord</SO>
<YR>2004</YR>
<VL>42</VL>
<NO>6</NO>
<PG>338-41</PG>
<IDENTIFIERS MODIFIED="2008-10-28 12:04:00 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-28 12:04:00 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="19336"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schurch-2004-B" NAME="Schurch 2004 B" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schurch B, de Seze M, Denys P, Chartier-Kastler E, Ismael S, Haab F, et al</AU>
<TI>Botulinum toxin A in neurogenic urinary incontinence: results from a multi-centre randomised, controlled trial (abstract)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>5/6</NO>
<PG>609-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19030"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schurch-2005-B" MODIFIED="2010-05-17 10:42:26 +0100" MODIFIED_BY="[Empty name]" NAME="Schurch 2005 B" YEAR="2005">
<REFERENCE MODIFIED="2010-05-17 10:42:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schurch B, De Seze M, Denys P, Chartier-Kastler E, Haab F, Evereart K et al</AU>
<TI>Subgroup analysis to determine impact of patient demographics on urodynamic response to focal administration of botulinum toxin A</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>5/6</NO>
<PG>545-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schurch-2006" MODIFIED="2010-05-17 10:43:04 +0100" MODIFIED_BY="[Empty name]" NAME="Schurch 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-05-17 10:43:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schurch B</AU>
<TI>Botulinum toxin in the treatment of neurogenic bladder in adults and children</TI>
<SO>European Urology, Supplements</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>11</NO>
<PG>679-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schurch-2007" MODIFIED="2010-05-17 10:43:39 +0100" MODIFIED_BY="[Empty name]" NAME="Schurch 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-05-17 10:43:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron RL</AU>
<TI>Botulinum toxin a improves the quality of life of patients with neurogenic urinary incontinence</TI>
<SO>European Urology</SO>
<YR>2007</YR>
<VL>52</VL>
<NO>3</NO>
<PG>850-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taha-2007" MODIFIED="2010-04-21 09:57:26 +0100" MODIFIED_BY="[Empty name]" NAME="Taha 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-21 09:57:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taha M, Farahat Y, Bahnasy A, Damhougy M</AU>
<TI>A randomized controlled trial of bacillus calmette-guerin and botulinum toxin-A for the treatment of refractory interstitial cystitis (Abstract number 107)</TI>
<SO>Neurourology &amp; Urodynamics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>5</NO>
<PG>735</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-04-22 09:37:58 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-11-08 14:49:05 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-11-08 14:49:05 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alhasso-2009" MODIFIED="2011-11-04 11:56:35 +0000" MODIFIED_BY="[Empty name]" NAME="Alhasso 2009" TYPE="COCHRANE_REVIEW">
<AU>Alhasso AA, McKinlay J, Patrick K, Stewart L</AU>
<TI>Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-11-04 09:33:12 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-04 09:33:12 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003193.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Apostolidis-2006" MODIFIED="2011-11-04 12:35:34 +0000" MODIFIED_BY="[Empty name]" NAME="Apostolidis 2006" TYPE="JOURNAL_ARTICLE">
<AU>Apostolidis A, Dasgupta P, Fowler C</AU>
<TI>Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity</TI>
<SO>European Urology</SO>
<YR>2006</YR>
<VL>49</VL>
<PG>644-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coyne-2009" MODIFIED="2011-11-04 11:56:59 +0000" MODIFIED_BY="[Empty name]" NAME="Coyne 2009" TYPE="JOURNAL_ARTICLE">
<AU>Coyne K, Wein A, Tubaro A, Sexton C, Thompson C, Kopp S, Aiyer L</AU>
<TI>The burden of lower urinary tract symptoms: evaluating the effects of LUTS on health-related quality of life, anxiety and depression: EpiLUTS</TI>
<SO>BJU International</SO>
<YR>2009</YR>
<VL>103</VL>
<NO>supplement 3</NO>
<PG>4-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cruz-2004" MODIFIED="2010-11-07 08:28:12 +0000" MODIFIED_BY="[Empty name]" NAME="Cruz 2004" TYPE="JOURNAL_ARTICLE">
<AU>Cruz F</AU>
<TI>Mechanisms involved in new therapies for overactive bladder</TI>
<SO>Urology</SO>
<YR>2004 March</YR>
<VL>63</VL>
<NO>supplement 3A</NO>
<PG>65-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Drake-2008" MODIFIED="2011-11-04 12:36:26 +0000" MODIFIED_BY="[Empty name]" NAME="Drake 2008" TYPE="JOURNAL_ARTICLE">
<AU>Drake M</AU>
<TI>Mechanisms of action of intravesical botulinum treatment in refractory detrusor overactivity</TI>
<SO>BJU International</SO>
<YR>2008</YR>
<VL>102</VL>
<NO>Supplement 1</NO>
<PG>11-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eustice-2000" MODIFIED="2011-11-03 11:58:15 +0000" MODIFIED_BY="[Empty name]" NAME="Eustice 2000" TYPE="COCHRANE_REVIEW">
<AU>Eustice S, Roe B, Paterson J</AU>
<TI>Prompted voiding for the management of urinary incontinence in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-11-03 11:58:15 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-03 11:58:15 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002113"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hay_x002d_Smith-2009" MODIFIED="2011-11-03 11:59:23 +0000" MODIFIED_BY="[Empty name]" NAME="Hay-Smith 2009" TYPE="COCHRANE_REVIEW">
<AU>Hay-Smith J, Ellis G, Herbison GP</AU>
<TI>Which antimuscarinic drug for overactive bladder symptoms in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-11-03 11:59:18 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-03 11:59:18 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005429"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Herbison-2009" MODIFIED="2011-11-03 12:00:06 +0000" MODIFIED_BY="[Empty name]" NAME="Herbison 2009" TYPE="COCHRANE_REVIEW">
<AU>Herbison GP, Arnold EP</AU>
<TI>Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-11-03 12:00:06 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-03 12:00:06 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004202.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ICS-2005" MODIFIED="2010-11-07 09:01:50 +0000" MODIFIED_BY="[Empty name]" NAME="ICS 2005" TYPE="OTHER">
<AU>International Continence Society</AU>
<TI>Fact Sheet 2: Overactive Bladder</TI>
<SO>www.icsoffice.org</SO>
<YR>July 2005</YR>
<IDENTIFIERS MODIFIED="2010-11-07 09:01:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Irwin-2006" MODIFIED="2011-11-04 11:58:52 +0000" MODIFIED_BY="[Empty name]" NAME="Irwin 2006" TYPE="JOURNAL_ARTICLE">
<AU>Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S et al</AU>
<TI>Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study</TI>
<SO>European Urology</SO>
<YR>2006 Dec</YR>
<VL>50</VL>
<NO>6</NO>
<PG>1306-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Irwin-2008" MODIFIED="2011-11-04 11:59:08 +0000" MODIFIED_BY="[Empty name]" NAME="Irwin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C</AU>
<TI>The economic impact of overactive bladder syndrome in six western countries</TI>
<SO>BJU International</SO>
<YR>2008</YR>
<VL>103</VL>
<PG>202-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nabi-2006" MODIFIED="2011-11-03 12:00:47 +0000" MODIFIED_BY="[Empty name]" NAME="Nabi 2006" TYPE="COCHRANE_REVIEW">
<AU>Nabi G, Cody DJ, Ellis G, Hay-Smith J, Herbison P</AU>
<TI>Anticholinergic drugs versus placebo for overactive bladder syndrome in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-11-03 12:00:47 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-03 12:00:47 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003781.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ostaszkiewicz-2004a" MODIFIED="2011-11-03 12:01:07 +0000" MODIFIED_BY="[Empty name]" NAME="Ostaszkiewicz 2004a" TYPE="COCHRANE_REVIEW">
<AU>Ostaszkiewicz J, Johnston L, Roe B</AU>
<TI>Timed voiding for the management of urinary incontinence in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-11-03 12:01:07 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-03 12:01:07 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002802.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ostaszkiewicz-2004b" MODIFIED="2011-11-03 12:01:17 +0000" MODIFIED_BY="[Empty name]" NAME="Ostaszkiewicz 2004b" TYPE="COCHRANE_REVIEW">
<AU>Ostaszkiewicz J, Johnston L, Roe B</AU>
<TI>Habit retraining for the management of urinary incontinence in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-11-03 12:01:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-03 12:01:17 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002801.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Roxburgh-2009" MODIFIED="2011-11-04 11:59:29 +0000" MODIFIED_BY="[Empty name]" NAME="Roxburgh 2009" TYPE="COCHRANE_REVIEW">
<AU>Roxburgh C, Cook J, Dublin N</AU>
<TI>Anticholinergic drugs versus other medications for overactive bladder syndrome in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-11-03 12:01:28 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-03 12:01:28 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003190.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wallace-2004" MODIFIED="2011-11-03 12:02:05 +0000" MODIFIED_BY="[Empty name]" NAME="Wallace 2004" TYPE="COCHRANE_REVIEW">
<AU>Wallace S, Roe B, Williams K, Palmer M</AU>
<TI>Bladder training for urinary incontinence in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-11-03 12:02:05 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-03 12:02:05 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001308.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2010-04-21 10:05:45 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-11-09 17:06:18 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-11-09 17:06:18 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-11-09 16:52:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brubaker-2008">
<CHAR_METHODS MODIFIED="2011-09-20 09:55:58 +0100" MODIFIED_BY="[Empty name]">
<P>"...multi-institutional, randomised, double-blind placebo controlled trial". </P>
<P>Power calculation performed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-04 11:21:38 +0000" MODIFIED_BY="[Empty name]">
<P>43 patients only women with IOAB refractory to pharmacological treatments. Particpants were</P>
<P>"neurologically intact women at least 21 years old with refractory urge incontinence, defined as inadequate symptom control after at least 2 first line therapies, which had to include 2 anticholinergic medications and at least 1 of supervised behavioural therapy" "inclusion required at least 6 urge incontinence episodes in a standardised 3 day bladder diary and documented urodynamic DOI within the last year"</P>
<P>Patients had on average 21.44 (BTX) and 19 (placebo) incontinence episodes in a 3 day bladder diary at baseline.</P>
<P>Average age at baseline were 64.7 (BTX) and 69.2 (placebo).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-09 16:52:48 +0000" MODIFIED_BY="[Empty name]">
<P>Intravesical BTX-A 200 U (n = 28) versus placebo (n = 15). Local anaesthetic administered then</P>
<P>"6 ml of masked substance were injected at approximately 15 to 20 detrusor muscle sites. Injections were spread out to cover the posterior bladder wall in 3 rows sparing the trigone and ureteric orifice"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 14:45:17 +0000" MODIFIED_BY="[Empty name]">
<P>Addressed Objective 1. PGI-I, PVR, Patient Global Symptom Control (PGSC), incontinence episodes.</P>
<P>"Primary outcome measure was time to failure (PGI-I 4 or greater), secondary outcome measure were changes in the frequency of incontinence episodes, changes in symptom and quality of life measures and the occurrence and duration of voiding dysfunction requiring catheterization."</P>
<P>"safety and adverse events were reported and monitored at 3 month intervals by an independent safety and monitoring board"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-04 11:21:53 +0000" MODIFIED_BY="[Empty name]">
<P>Power calculation suggested required sample size of 210 participants. The study was stopped due to high rates of urinary retention (as defined by PVR of &gt;200 ml), and UTI. Follow up was planned from 4 weeks up to 12 months.</P>
<P>Full publication and 2 abstracts.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-09 16:53:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ehren-2007">
<CHAR_METHODS MODIFIED="2011-09-20 09:55:52 +0100" MODIFIED_BY="[Empty name]">
<P>"...randomised, placebo controlled, double-blind study". </P>
<P>No power calculation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-04 12:19:22 +0000" MODIFIED_BY="[Empty name]">
<P>31 patients; 17 male,and 14 female. NOAB with urinary incontinence caused by spinal cord injury in 20, myelomeningocele in 2, birth trauma in 2, MS in 6, and myelitis in 1.</P>
<P>"inclusion criteria were as follows: age &#8805;18 years, urodynamically proven detrusor overactivity with urinary leakage for at least 1 year, inadequate response to oral anticholinergics, and ability to perform clean intermittent catheterization."</P>
<P>Mean age of patients was 36 years (range 21 to 66)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-09 16:53:18 +0000" MODIFIED_BY="[Empty name]">
<P>500 U BTX-A (n = 17) versus placebo (n = 14).</P>
<P>"under cystoscopic guidance, 25 1.0 ml aliquots were injected intramuscularly into the detrusor, avoiding the trigone and ureteric orifices. Injections were performed under local or general anaesthesia."</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-04 12:19:44 +0000" MODIFIED_BY="[Empty name]">
<P>Addressed Objective 1. Follow up at 6, 12, and 26 weeks. Tolterodine consumption, MCC, MDP, incontinence episodes, QoL.</P>
<P>"patients were followed for 26 weeks. Episodes of urinary leakage were registered daily in the diary during the study, Cystometry was performed after 6, 12 and 26 weeks and maximum detrusor pressure and maximum bladder capacity were registered. Quality of life was also assessed by means of the Qualiveen questionnaire at these points. Safety evaluations were based upon spontaneous reports of adverse events at the patient visits"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-20 00:39:43 +0100" MODIFIED_BY="[Empty name]">
<P>4 in placebo group did not complete study. Anticholinergics discontinued 1 week prior to starting trial and only initiated again if no response 1 week after injection. </P>
<P>Full publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-09 16:53:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Finney-2006">
<CHAR_METHODS MODIFIED="2011-09-20 09:55:46 +0100" MODIFIED_BY="[Empty name]">
<P>Double-bind placebo controlled trial. </P>
<P>No power calculation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-20 10:10:46 +0100" MODIFIED_BY="[Empty name]">
<P>20 patients with MS and OAB with at least episode of incontinence per day. </P>
<P>"Diagnosis of MS for at least 1 year made by a consultant neurologist......Each also has OAB diagnosed by a consultant urologist......All had urodynamically proven detrusor overactivity and had found anticholinergics either ineffective or their side effects intolerable."</P>
<P>"patients with symptoms of stress related incontinence were excluded"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-09 16:53:37 +0000" MODIFIED_BY="[Empty name]">
<P>500 U BTX-A (n = 10), versus placebo (n = 10). "injections were performed by flexible cystoscopy."</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-04 12:20:20 +0000" MODIFIED_BY="[Empty name]">
<P>Addressed Objective 1. Frequency, nocturia, incontinence, 24 hour pad weights, MCC, PVR.</P>
<P>"continence diaries assessing daytime frequency, nocturia, and episodes of leakage were completed for 3 consecutive days prior to injection, at 12 weeks and 36 weeks....Urodynamics were performed at baseline, 6 weeks and 36 weeks.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-20 09:49:53 +0100" MODIFIED_BY="[Empty name]">
<P>Follow up at 12 and 36 weeks. 7 of 10 patients from placebo group dropped out at 12 weeks, and patients experiencing no improvement at 12 weeks were withdrawn. </P>
<P>Abstract only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-09 16:53:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flynn-2009">
<CHAR_METHODS MODIFIED="2011-09-21 10:41:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, placebo controlled, double-blinded study. </P>
<P>Power calculation performed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-03 15:25:28 +0000" MODIFIED_BY="[Empty name]">
<P>22 patients with IOAB refractory to antimuscarinics with two or more leakage episodes per day and 24 hour pad weights greater than 100 g.</P>
<P>"at least 1 anticholinergic medication and behavioural modifications must have failed in subjects before they entered the trial"</P>
<P>"we allowed subjects with coexisting severe OAB and mild stress incontinence to enter the study. To minimise the impact of the stress component of the leakage and eliminate subjects with intrinsic sphincter deficiency, subjects could not have a cough leak point pressure less than 100 cm H<SUB>2</SUB>O."</P>
<P>"all anticholinergic medications were stopped 10 days before study entry"</P>
<P>"patients were excluded from the study if they had any known neurological condition"</P>
<P>Patients had 8 incontinence episodes per day on average at baseline.</P>
<P>Mean age was 66(41 to 85)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-09 16:53:58 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo versus BTX-A 200 U (n = 7) or 300 U (n = 15). Local anaesthetic and rigid cystoscope.</P>
<P>"staying superior to the trigone and medial to the ureteric orifices, the detrusor was injected with approximately 0.2 cc study solution per site at 10 to 12 sites.."</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 14:45:49 +0000" MODIFIED_BY="[Empty name]">
<P>Addressed Objective 4. Urodynamics, UDI-6, IIQ-7, bladder diaries, pad usage.</P>
<P>"primary outcomes were the number of incontinence episodes per 24 hours........and scores on UDI-6 and IIQ-7"</P>
<P>"at all interactions subjects were assessed using a verbal questionnaire for evidence of adverse effects"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-20 10:39:46 +0100" MODIFIED_BY="[Empty name]">
<P>2 phase study, currently only phase 1 is reported. Follow up at 6 weeks. </P>
<P>Full publication and 3 abstracts.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-03 15:26:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghei-2005">
<CHAR_METHODS MODIFIED="2011-09-21 10:41:01 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blinded, crossover study. </P>
<P>Power calculation performed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-03 15:26:18 +0000" MODIFIED_BY="[Empty name]">
<P>20 participants with IOAB or NOAB on urodynamics. 3 males, 17 females, mean age 50 years.</P>
<P>"ages 18 to 81 with neurological and non neurological detrusor overactivity demonstrated by urodynamics"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-03 15:26:23 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo or 5,000 U BTX-B. Participants crossed over to other arm at 6 weeks.</P>
<P>"5000 U of Botulinum-B (diluted up to 20 ml) or 20 ml of placebo, as allocated, were injected into the detrusor over the same 10 different injection sites, sparing the trigone, by the same surgeon."</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-20 11:29:20 +0100" MODIFIED_BY="[Empty name]">
<P>Addressed objective 1. Void volume, incontinence episodes, weekly frequency, QoL, adverse events.</P>
<P>"primary outcome measure was the paired difference in change in average voided volume. frequency, incontinence episodes and quality of life were secondary outcome measures"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-20 11:32:51 +0100" MODIFIED_BY="[Empty name]">
<P>Follow up at 2 and 6 weeks after each procedure. </P>
<P>power calculation required 20 pairs of cases.</P>
<P>2 full publications.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-09 16:54:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giannantoni-2004">
<CHAR_METHODS MODIFIED="2011-09-25 09:52:26 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, unblinded, single centre, parallel study; </P>
<P>"selected and randomised by commercially available software".</P>
<P>No power calculation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-04 11:31:15 +0000" MODIFIED_BY="[Empty name]">
<P>25 patients with NOAB; 18 males, 7 females. Mean age 38 yrs.</P>
<P>"Mean age SD was 38.4 +/- 12.5 years and mean disease duration was 41.8 +/- 16.5 months"</P>
<P>"A total of 20 patients had a lesion at the thoracic level while the remaining patients showed a cervical injury"</P>
<P>"Inclusion criteria were unacceptable clinical (patient driven) and urodynamic suppression of detrusor activity (author assessment) by oral and intravesical oxybutynin, intolerable anticholinergic side effects, normal renal function, no vesicoureteral reflux and a normal upper urinary tract"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-09 16:54:08 +0000" MODIFIED_BY="[Empty name]">
<P>Either intravesical instillation of resiniferatoxin (n = 13), or 300 U intradetrusor BTX-A (12).</P>
<P>"Patients in group 1 (13) received intravesical administrations of RTX for 45 minutes through a polyvinyl chloride catheter with real-time cystometrography as outpatients"</P>
<P>"Patients in group 2 (12) were injected with 300 units of commercially available botulinum-A toxin diluted in 30 ml 0.9% NaCl into the detrusor muscle (30 sites, sparing the trigone) under cystoscopic control"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-03 12:19:57 +0000" MODIFIED_BY="[Empty name]">
<P>Addressed objective 2. Number of catheterizations, incontinence episodes, urodynamics.</P>
<P>"Patients recorded the number of daily catheterizations and episodes of incontinence"</P>
<P>"Urodynamic studies were repeated at 6, 12 and 18-month follow up"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-25 09:01:13 +0100" MODIFIED_BY="[Empty name]">
<P>Follow up at 6,12, and 18 weeks. </P>
<P>Full Publication.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-09 16:54:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gousse-2005">
<CHAR_METHODS MODIFIED="2011-09-25 09:24:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, prospective, dose-finding trial.</P>
<P>No power calculation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-25 09:12:40 +0100" MODIFIED_BY="[Empty name]">
<P>44 participants with IOAB, 24 patients had OAB-wet, 20 patients had OAB-dry.</P>
<P>"subjects were required to have either failed or have been unable to tolerate treatment with at least 2 different anti-muscarinic agents and have been treated with these agents for at least 2 months"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-09 16:54:30 +0000" MODIFIED_BY="[Empty name]">
<P>BTX-A in either 100 U (n = 22) or 150U (n = 22) dose. Re-injected every 6 months.</P>
<P>"injected in an office setting"</P>
<P>"bladder was instilled with 40ml of 1% lidocaine solution"</P>
<P>"supra-trigonal detrusor muscle was injected with BTX-A 10 units/ml in 10 to 15 separate sites"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-04 12:21:53 +0000" MODIFIED_BY="[Empty name]">
<P>Addressed objective 4. Void volume, daily frequency, QoL, adverse events.</P>
<P>"CIC was recommended to symptomatic patients with PVR &gt;100 ml and asymptomatic patients with PVR &gt;200 ml"</P>
<P>"PVR, 3-VD data and adverse events were obtained at clinic visits at 2, 6, 12 and 24 weeks"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-25 09:01:23 +0100" MODIFIED_BY="[Empty name]">
<P>Follow up at 6 to 24 months. </P>
<P>Full publication and 13 abstracts.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-03 15:27:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grise-2008">
<CHAR_METHODS MODIFIED="2011-11-03 15:27:37 +0000" MODIFIED_BY="[Empty name]">
<P>Prospective, randomised, multi-centre clinical study.</P>
<P>No power calculation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-20 11:58:20 +0100" MODIFIED_BY="[Empty name]">
<P>77 patients with NOAB. Underlying pathology is spinal cord injury in 49, MS in 18, other causes in 10.</P>
<P>"14 day wash out period without anticholinergic treatment was required, then no anticholinergic were authorised during the study period"</P>
<P>"bladder tumour, lithiasis and urinary retention were excluded"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-03 14:18:07 +0000" MODIFIED_BY="[Empty name]">
<P>BTX-A 500 U (n not given) versus 750 U (n not given).</P>
<P>"injections were extra trigonal in the detrusor muscle"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-20 11:53:19 +0100" MODIFIED_BY="[Empty name]">
<P>Addressed Objective 4. Continence.</P>
<P>"onset of urinary incontinence was considered as failure of the treatment"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-20 11:56:18 +0100" MODIFIED_BY="[Empty name]">
<P>Follow up at 30 days, 90, 180, and 360 days. </P>
<P>Abstract only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-09 16:54:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herschorn-2009">
<CHAR_METHODS MODIFIED="2011-09-21 10:40:22 +0100" MODIFIED_BY="[Empty name]">
<P>Multicentre, randomised, double-blind trial. </P>
<P>Power calculation performed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-03 14:18:25 +0000" MODIFIED_BY="[Empty name]">
<P>57 participants; 34 male, 23 female. NOAB associated with spinal injury(38) or MS(19) refractory to antimuscarinics.</P>
<P>Mean age 42.8 years (32 to 50)</P>
<P>"eligible for inclusion if they had urinary incontinence (minimum of 1 occurrence per day) despite current anticholinergic treatment".</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-09 16:54:51 +0000" MODIFIED_BY="[Empty name]">
<P>BTX-A 300 U (n = 12) vs placebo (n = 14).</P>
<P>"with a flexible or rigid cystoscopic injection needle at 30 intra-detrusor sites, sparing the trigone."</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-20 12:10:29 +0100" MODIFIED_BY="[Empty name]">
<P>Addresses Objective 1. Urodynamics, I-QOL, ICIQ.</P>
<P>"primary efficacy parameter was the frequency of incontinence episodes"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-20 12:14:35 +0100" MODIFIED_BY="[Empty name]">
<P>Follow up at 6 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks. </P>
<P>2 abstracts only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-08 14:46:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karsenty-2005">
<CHAR_METHODS MODIFIED="2011-11-03 14:18:41 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised, single-blinded trial.</P>
<P>No power calculation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 14:46:13 +0000" MODIFIED_BY="[Empty name]">
<P>24 participants with NOAB, 15 females, 9 males.</P>
<P>"NDOI related to traumatic chronic spinal lesion (15), MS (8) or myelomeningocele (1)."</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-03 15:28:21 +0000" MODIFIED_BY="[Empty name]">
<P>300 U BTX-A injected into either 10 (n not given) or 30 (n not given) intravesical sites.</P>
<P>"injections were done under local anaesthesia"</P>
<P>"trigone was not injected"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-21 09:23:42 +0100" MODIFIED_BY="[Empty name]">
<P>Addressed objective 7. Bladder capacity, incontinence episodes, QoL. Primary endpoint was improvement in cystomanometric bladder capacity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-21 09:24:07 +0100" MODIFIED_BY="[Empty name]">
<P>Follow up at 6, 12, and 24 weeks. </P>
<P>Abstract only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-09 16:55:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-King-2007">
<CHAR_METHODS MODIFIED="2011-09-21 10:39:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo controlled trial. </P>
<P>Power calculation performed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-04 12:22:43 +0000" MODIFIED_BY="[Empty name]">
<P>31 patients with refractory idiopathic detrusor overactivity, all women between 18 and 85.</P>
<P>"urodynamically documented DO, no neurological disease or injury and minimal response to current treatments"</P>
<P>"no significant difference in age between the two arms (60.7 versus 64.3 years)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-09 16:55:21 +0000" MODIFIED_BY="[Empty name]">
<P>BTX-A 200 U (n = 15) versus placebo (n = 16).</P>
<P>"Under general anaesthesia 10 sites were injected subepithelially over the trigone and 10 sites on the bladder base"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-15 07:06:37 +0000" MODIFIED_BY="[Empty name]">
<P>Addressed Objective 1. Incontinence episodes, nocturia, frequency.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-21 09:31:57 +0100" MODIFIED_BY="[Empty name]">
<P>Follow up at 6 weeks, those with improvement continued for 9 months. Initial flow test at 2 weeks to exclude significant PVR.</P>
<P>Power calculation suggested 15 patients required in each arm.</P>
<P>Abstract only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-09 16:55:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuo-2006">
<CHAR_METHODS MODIFIED="2011-09-21 10:39:37 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective randomised controlled trial.</P>
<P>No power calculation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-09 16:55:39 +0000" MODIFIED_BY="[Empty name]">
<P>75 patients (32 women, 43 men) with detrusor overactivity (40 neurogenic, 35 idiopathic) refractory to antimuscarinics. Patients with high PVR pre-treatment were excluded.</P>
<P>"75 patients with NDO or IDO in whom antimuscarinic treatment using tolterodine 4 mg/day during the previous 3 months had failed were enrolled"</P>
<P>"mean patient age was 63.4 +/- 10.7 years"</P>
<P>"The use of anticholinergic agents was discontinued before BTX-A injection"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-09 16:55:58 +0000" MODIFIED_BY="[Empty name]">
<P>BTX-A 100 U (n = 23) versus 150 U (n = 25) versus 200 U (n = 27), suburothelial injections.</P>
<P>"under intravenous general anaesthesia in the operation room"</P>
<P>"Suburothelial injection of BTX-A was<BR/>"performed at 40 sites in the posterior and lateral walls of the urinary bladder"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-08 14:46:31 +0000" MODIFIED_BY="[Empty name]">
<P>Assessed Objective 4. Bladder capacity, MDP, Peak flow rate (Qmax), PVR, voiding efficiency, therapeutic effect.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-03 14:20:01 +0000" MODIFIED_BY="[Empty name]">
<P>Follow up at 4 and 12 weeks.</P>
<P>Full publication and abstract.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-09 16:56:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuo-2007">
<CHAR_METHODS MODIFIED="2011-09-21 10:39:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
<P>No power calculation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-08 14:46:58 +0000" MODIFIED_BY="[Empty name]">
<P>45 patients with detrusor overactivity refractory to antimuscarinics.</P>
<P>"urodynamically proven DO and unsuccessful antimuscarinic therapy"</P>
<P>"Patients with neurogenic bladder, bladder outlet obstruction or urinary tract infection were excluded from the study"</P>
<P>"The mean age and gender distribution were not significantly different among the 3 groups"</P>
<P>"Mean pt age 72.1 +/- 10.3 (suburothelial) 71.6 +/- 13.6 (detrusor) 67.9+/-12.1(bladder base)"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-09 16:56:23 +0000" MODIFIED_BY="[Empty name]">
<P>BTX-A 100U administered as detrusor (n = 15), suburothelial (n = 15), or bladder base (n = 15) injections.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-21 10:07:11 +0100" MODIFIED_BY="[Empty name]">
<P>Assessed Objective 7. Urodynamics, symptom score, urgency/incontinence episodes, severity score, satisfaction rating.</P>
<P>"primary end point assessed was the effectiveness of the different intravesical BTX-A injections as determined by the general satisfaction rating"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-25 09:00:27 +0100" MODIFIED_BY="[Empty name]">
<P>Patients followed up at 1 week, 2 weeks, 4 weeks, and at monthly intervals thereafter until therapeutic effect lost. Majority of results published for 3 month interval. </P>
<P>Full publication and abstract.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-03 14:21:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lucioni-2008">
<CHAR_METHODS MODIFIED="2011-09-21 10:52:29 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
<P>"prospective, randomised study"</P>
<P>No power calculation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-03 14:20:37 +0000" MODIFIED_BY="[Empty name]">
<P>30 patients with detrusor overactivity refractory to high dose antimuscarinics.</P>
<P>"Patients failing high-dose anticholinergic therapy for DO underwent cystoscopy and bladder injection of BTX"</P>
<P>"Mean patient age was 70 years (33 to 89 years)"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-03 14:20:54 +0000" MODIFIED_BY="[Empty name]">
<P>BTX-A 200 U as 30 injections given as 0.1 (n not given), 0.5 (n not given), or 1 cc (n not given) injections.</P>
<P>"All patients received a total of 200 units of BTX divided among thirty evenly distributed intramural injections. Patients were randomised to receive injection volumes of 0.1 cc, 0.5 cc, or 1.0 cc per injection"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-21 10:36:21 +0100" MODIFIED_BY="[Empty name]">
<P>Addressed Objective 7. UDI-6, IIQ-7 and urodynamics.</P>
<P>"Patient response to BTX was determined by UDI-6 and IIQ-7 questionnaires (subjective evaluation) as well as urodynamics (objective evaluation)"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-03 14:21:03 +0000" MODIFIED_BY="[Empty name]">
<P>1 patient did not complete follow up. Follow up at 6 to 8 weeks and at 6 months.</P>
<P>Abstract only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-03 14:21:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moore-2009">
<CHAR_METHODS MODIFIED="2011-09-21 10:44:52 +0100" MODIFIED_BY="[Empty name]">
<P>Double-blind, placebo controlled, randomised crossover trial of trigone specific injections.</P>
<P>Crossover study</P>
<P>Power calculation performed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-12-15 07:13:47 +0000" MODIFIED_BY="[Empty name]">
<P>20 patients with idiopathic detrusor overactivity refractory to at least 2 antimuscarinics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-03 14:21:15 +0000" MODIFIED_BY="[Empty name]">
<P>BTX-B 5000 U versus placebo given as trigone specific injections in 3 sites.</P>
<P>"after 10 weeks they were crossed over to receive the other treatment"</P>
<P>"all injections were administered using the same anaesthetic method ...... injected with a rigid cystoscope"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-12-15 07:14:24 +0000" MODIFIED_BY="[Empty name]">
<P>Voiding diaries, UDI-6 and Kings Health Questionnaire.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-21 10:45:15 +0100" MODIFIED_BY="[Empty name]">
<P>Follow up at 2 and 10 weeks after each injection. </P>
<P>Power calculation required 20 patients.</P>
<P>Abstract only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-09 16:56:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sahai-2005">
<CHAR_METHODS MODIFIED="2011-09-21 10:59:46 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blinded, single centre trial.</P>
<P>Power calculation performed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-21 11:14:45 +0100" MODIFIED_BY="[Empty name]">
<P>34 patients with at least 6 months of symptoms and urodynamically proven idiopathic detrusor overactivity. Mean age 50.3, mixed sex. All had failed at least 6 weeks of antimuscarinics.</P>
<P>"in a trial of anticholinergics for 6 weeks or more before randomisation treatment failed due to poor efficacy or tolerability"</P>
<P>urge incontinence episodes occurred 4.98 times/day in BTX group and 3.91 times/day in placebo group at baseline.</P>
<P>Anticholinergics were not forbidden.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-09 16:56:41 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 18) or BTX-A 200 U (n = 16).</P>
<P>"the minimally invasive technique involved 20 injections at 10 U/ml per injection site into the bladder wall, sparing the trigone."</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-04 11:39:15 +0000" MODIFIED_BY="[Empty name]">
<P>Addressed Objective 1. Urodynamics, QoL, frequency, incontinence episodes, PVR, adverse events. 3 day voiding diary. Use of antimuscarinics</P>
<P>"primary endpoint was change in MCC"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-21 11:00:40 +0100" MODIFIED_BY="[Empty name]">
<P>Telephone follow up at 1 week and formal review at 4 weeks and 12 weeks. </P>
<P>Power calculation required 16 patients in each group.</P>
<P>2 full publications and 2 abstracts.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-09 16:57:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schurch-2005">
<CHAR_METHODS MODIFIED="2011-09-25 09:28:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blinded, multicentre, parallel trial.</P>
<P>"patients from 8 centres in Belgium, France and Switzerland."</P>
<P>Power calculation performed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-04 11:24:34 +0000" MODIFIED_BY="[Empty name]">
<P>59 participants with NOAB. 36 males, 23 female, age over 18 years. All had symptoms for at least 6 weeks, performed regular CIC, and had failed a trial of antimuscarinics.</P>
<P>"urinary incontinence caused by neurogenic detrusor overactivity (NDO) with spinal cord injury (53 patients) or multiple sclerosis (6 patients)."</P>
<P>"Patients had experienced an inadequate response to oral anticholinergics; however, concomitant use of these agents at stable dosages was allowed during the study for ethical reasons."</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-09 16:57:21 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo (n = 21), 200 U BTX-A (n = 19), or 300 U (n = 19) BTX-A. Given as 30 trigone sparing injections of 1ml.</P>
<P>"as 30 1.0 ml cystoscopically guided injections into the detrusor, sparing the trigone"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-25 08:35:33 +0100" MODIFIED_BY="[Empty name]">
<P>Addressed Objectives 1 and 4. Incontinence episodes, urodynamics, QoL, adverse events.</P>
<P>"Follow-up visits occurred at weeks 2, 6, 12, 18, and 24, during which clinical and I-QOL evaluations were performed"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-25 08:35:40 +0100" MODIFIED_BY="[Empty name]">
<P>Follow up at 2, 6, 12,18 and 24 weeks. </P>
<P>2 full publications and 2 abstracts.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-04 11:39:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thavaseelan-2005">
<CHAR_METHODS MODIFIED="2011-09-25 09:27:48 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, single centre, parallel groups.</P>
<P>No power calculation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-09-25 08:46:41 +0100" MODIFIED_BY="[Empty name]">
<P>56 patients with NOAB due to spinal cord pathology.</P>
<P>"56 patients with spinal pathology who self catheterise and failed anticholinergic treatment."</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-04 11:39:23 +0000" MODIFIED_BY="[Empty name]">
<P>200 U BTX-A (n not given) or 300 U BTX-A (n not given).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-09-25 08:51:37 +0100" MODIFIED_BY="[Empty name]">
<P>Addressed Objective 4. Interim results commenting on efficacy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-25 08:47:01 +0100" MODIFIED_BY="[Empty name]">
<P>5-day bladder diary and urodynamics at 6, 12, 24, and 52 weeks. </P>
<P>Abstract only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-09 17:06:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Truzzi-2004">
<CHAR_METHODS MODIFIED="2011-09-25 09:27:21 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, blinded, parallel dose finding trial.</P>
<P>No power calculation.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-09 17:06:18 +0000" MODIFIED_BY="[Empty name]">
<P>14 participants, 13 with NOAB, 1 with IOAB. Aged 14 to 62.</P>
<P>"mean age of 33 y.o."</P>
<P>"all but one suffer from neurogenic bladder (12 due to spinal; cord injury and 1 to neuroschistosomiasis). The non-neurogenic one was considered with an idiopathic etiology."</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-09 16:57:53 +0000" MODIFIED_BY="[Empty name]">
<P>BTX-A 100 U (n = 8) or BTX-A 300 U (n = 6).</P>
<P>"cystoscopy was performed under general anaesthesia with injection of 1ml of saline solution or Botox in each of thirty points"</P>
<P>"they were asked to perform clean intermittent catheterization four times a day"</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-04 11:39:43 +0000" MODIFIED_BY="[Empty name]">
<P>Addressed Objective 4. MCC, MDP, continence.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-09-25 08:59:26 +0100" MODIFIED_BY="[Empty name]">
<P>Follow up at 30, 60, and 90 days. </P>
<P>Abstract only.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BTX = botulinum toxin; BTX-A = botulinum toxin A; BTX-B = botulinum toxin B; DCC = Data Coordinating Center; DOI = Detrusor Overactivity Incontinence; DO = Detrusor Overactivity; IDO = Idiopathic Detrusor Overactivity; IOAB = idiopathic overactive bladder; MCC = maximum cystometric capacity; MDP = maximum detrusor pressure; MS = multiple sclerosis; NaCI = sodium chloride; NDO=neurogenic detrusor overactivity; NDOI = Neurogenic Detrusor Overactivity Incontinence; NOAB = neurogenic overactive bladder; OAB = overactive bladder syndrome; PGI-I = Patient Global Imression of Improvement index; PGSC = Patient Global Symptom Control; PVR = post void residual volume; QoL=quality of life; UTI = urinary tract infection; yrs = years; y.o = year old.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-11-04 11:52:11 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-12-15 07:25:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brubaker-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 07:25:17 +0000" MODIFIED_BY="[Empty name]">
<P>No data, methods of trial only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:19:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brubaker-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:19:42 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:19:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brubaker-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:19:44 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-26 10:01:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caruso-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-26 10:01:26 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-17 09:57:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-17 09:57:05 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-15 07:26:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 07:26:13 +0000" MODIFIED_BY="[Empty name]">
<P>Pre-injection predictors of success of BTX, not outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:19:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:19:47 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-15 07:26:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-2009a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 07:26:18 +0000" MODIFIED_BY="[Empty name]">
<P>Pre-injection predictors of success of BTX, not outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-15 07:26:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cui-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 07:26:54 +0000" MODIFIED_BY="[Empty name]">
<P>Studies detrusor-sphincter dyssynergia, not OAB.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-de-Seze-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Studies detrusor-sphincter dyssynergia, not OAB.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dykstra-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Studies detrusor-sphincter dyssynergia, not OAB.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-15 07:27:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Farid-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 07:27:15 +0000" MODIFIED_BY="[Empty name]">
<P>Studies anismus, not OAB.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-15 07:27:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Farid-2009a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 07:27:16 +0000" MODIFIED_BY="[Empty name]">
<P>Studies anismus, not OAB.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:19:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flynn-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:19:51 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:19:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flynn-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:19:53 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:19:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flynn-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:19:54 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-15 07:27:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gallien-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 07:27:29 +0000" MODIFIED_BY="[Empty name]">
<P>Studies detrusor-sphincter dyssynergia, not OAB.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:19:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghei-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:19:57 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-15 07:28:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghei-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 07:28:01 +0000" MODIFIED_BY="[Empty name]">
<P>4 case studies of patients suffering side effects from BTX.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Giannantoni-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Giannantoni-2004B">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gousse-2005-B">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study on pain tolerance during endoscopy for administration of intravesical BTX. Does not investigate efficacy of BTX.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gousse-2005a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:00 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gousse-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:01 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gousse-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:02 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gousse-2007b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:04 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gousse-2007c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:05 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gousse-2007d">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:07 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gousse-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:09 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gousse-2008a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:10 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gousse-2008b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:12 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gousse-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:13 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herschorn-2009a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:15 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-15 07:28:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keshtgar-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 07:28:32 +0000" MODIFIED_BY="[Empty name]">
<P>Studies constipation, not OAB.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-15 07:28:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kessler-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 07:28:38 +0000" MODIFIED_BY="[Empty name]">
<P>Editorial/correspondence, not a new study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuo-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:18 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-15 07:28:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuo-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 07:28:59 +0000" MODIFIED_BY="[Empty name]">
<P>Studies urethral injections, not intravesical.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-15 07:29:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuo-2007b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 07:29:32 +0000" MODIFIED_BY="[Empty name]">
<P>Studies urethral injections, not intravesical.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuo-2007c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:19 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-15 07:29:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maria-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 07:29:38 +0000" MODIFIED_BY="[Empty name]">
<P>Studies chronic anal fissure, not OAB.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maria-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Studies benign prostatic hyperplasia, not OAB.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-15 07:30:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Neel-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-15 07:30:03 +0000" MODIFIED_BY="[Empty name]">
<P>Studies patients with noncompliant bladder, not OAB</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ron-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Studies anismus, not OAB.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sahai-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:22 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sahai-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:23 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sahai-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:24 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-04 11:51:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schurch-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-04 11:51:57 +0000" MODIFIED_BY="[Empty name]">
<P>Studies pain relief during intravesical injections, not effect of BTX.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schurch-2004-B">
<CHAR_REASON_FOR_EXCLUSION>
<P>Studies urinary incontinence, not OAB.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schurch-2005-B">
<CHAR_REASON_FOR_EXCLUSION>
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schurch-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:26 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-21 10:20:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schurch-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-21 10:20:28 +0100" MODIFIED_BY="[Empty name]">
<P>Further report from study included in review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-11-04 11:52:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taha-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-11-04 11:52:05 +0000" MODIFIED_BY="[Empty name]">
<P>Studies interstitial cystitis, not OAB.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>BTX = Botulinum toxin; OAB = overactive bladder.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-04-22 09:37:58 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2011-11-08 14:45:59 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2011-11-08 14:45:27 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 14:45:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brubaker-2008">
<DESCRIPTION>
<P>"randomisation (2:1 Botox or placebo) is performed using a random block size that is known only to the Data Coordinating Center (DCC)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-03 14:13:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ehren-2007">
<DESCRIPTION>
<P>Unclear.</P>
<P>"patients were randomised to treatment with either 500 U of BTX-A or placebo" methods of randomisation were not stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-25 08:58:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Finney-2006">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 06:57:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flynn-2009">
<DESCRIPTION>
<P>Random number generator. Subjects randomised in blocks of 6.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-20 12:30:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ghei-2005">
<DESCRIPTION>
<P>Random number generator.</P>
<P>"a computerised random number generator was used by the clinical trials pharmacist to draw up a randomisation schedule"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-25 09:51:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giannantoni-2004">
<DESCRIPTION>
<P>Computer generated randomisation.</P>
<P>"randomised by commercially available software into 2 groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-25 09:20:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gousse-2005">
<DESCRIPTION>
<P>"based upon a random number generator with numbers pre-assigned to the two doses"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-25 09:03:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grise-2008">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-25 09:05:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Herschorn-2009">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:04:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karsenty-2005">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:07:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-King-2007">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:09:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuo-2006">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:11:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuo-2007">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-21 10:42:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lucioni-2008">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-21 10:53:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2009">
<DESCRIPTION>
<P>Computer generated</P>
<P>"Randomisation was computer generated".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-10 08:37:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sahai-2005">
<DESCRIPTION>
<P>"An independent statistician generated the randomisation code using SAS version 8.2 software".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-25 08:40:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schurch-2005">
<DESCRIPTION>
<P>"each patient was allocated a unique randomisation number"</P>
<P>"randomised in a 1:1:1 ratio"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:22:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thavaseelan-2005">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-03 14:23:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Truzzi-2004">
<DESCRIPTION>
<P>"The dose (100 U or 300 U) was chosen by chance, immediately before the procedure".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-11-03 14:12:32 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-03 14:12:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brubaker-2008">
<DESCRIPTION>
<P>"study coordinator selects next available randomisation number from a stratified list provided by the DCC that corresponds to a envelope that the pharmacist opens."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:04:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ehren-2007">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-25 08:58:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Finney-2006">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-10 08:03:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flynn-2009">
<DESCRIPTION>
<P>"Study assignments were assigned via sealed, sequentially numbered opaque envelopes."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-10 08:07:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ghei-2005">
<DESCRIPTION>
<P>"Identical packages were produced...the contents of these were known only to the clinical trials pharmacist."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-25 08:58:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giannantoni-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-25 09:21:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gousse-2005">
<DESCRIPTION>
<P>"sealed envelopes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-25 09:03:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grise-2008">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-25 09:05:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Herschorn-2009">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:03:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karsenty-2005">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:07:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-King-2007">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:09:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuo-2006">
<DESCRIPTION>
<P>None.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:11:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kuo-2007">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:13:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lucioni-2008">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:14:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moore-2009">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-10 08:38:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sahai-2005">
<DESCRIPTION>
<P>"Both preparations were clear and appeared identical".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:21:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schurch-2005">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:22:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thavaseelan-2005">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:24:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Truzzi-2004">
<DESCRIPTION>
<P>By chance immediately before procedure.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-09-25 08:48:48 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-09-20 12:29:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brubaker-2008">
<DESCRIPTION>
<P>Patient, doctor, and study coordinator all blinded.</P>
<P>"syringes were prepared by a study pharmacist and they appeared identical to the injecting physician"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-09-20 00:50:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ehren-2007">
<DESCRIPTION>
<P>Unclear.</P>
<P>"double-blind study" no details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-10 08:01:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Finney-2006">
<DESCRIPTION>
<P>Double-blinded; "with the investigators and recruits; double blinded..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-16 10:05:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flynn-2009">
<DESCRIPTION>
<P>Double blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-15 06:58:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ghei-2005">
<DESCRIPTION>
<P>Drugs prepared by nurse; patients and doctors blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-25 08:57:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Giannantoni-2004">
<DESCRIPTION>
<P>Patients and doctors unblinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-25 09:00:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gousse-2005">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-25 09:03:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Grise-2008">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-25 09:05:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Herschorn-2009">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-15 07:03:26 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karsenty-2005">
<DESCRIPTION>
<P>States patient blinding not assessors.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-15 07:07:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-King-2007">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-15 07:10:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuo-2006">
<DESCRIPTION>
<P>Single-blinded (patients).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-09-21 10:11:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kuo-2007">
<DESCRIPTION>
<P>Double-blind; </P>
<P>"The outcome parameters were measured by a research assistant who was not aware of the treatment assignments".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-15 07:13:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lucioni-2008">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-10 08:36:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2009">
<DESCRIPTION>
<P>"patients, practitioners, and assessors were blinded to the treatment given".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-10 08:38:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sahai-2005">
<DESCRIPTION>
<P>"Clinicians and patients were blinded".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-02-10 08:47:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schurch-2005">
<DESCRIPTION>
<P>"This double-blind, randomised, placebo controlled, parallel group study..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-09-25 08:48:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thavaseelan-2005">
<DESCRIPTION>
<P>"a prospective, randomised, double blind trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-15 07:24:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Truzzi-2004">
<DESCRIPTION>
<P>Patients only.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-04-22 08:58:19 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-04-22 08:58:19 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-11-08 14:45:59 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-20 01:07:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brubaker-2008">
<DESCRIPTION>
<P>BTX provided by Allergan.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 06:55:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ehren-2007">
<DESCRIPTION>
<P>Ipsen grant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-22 09:18:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Finney-2006">
<DESCRIPTION>
<P>Ispen funded trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-08 14:45:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Flynn-2009">
<DESCRIPTION>
<P>Authors have relationships with Pfizer, Lifetech, and AMS.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ghei-2005">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-25 09:00:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giannantoni-2004">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:00:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gousse-2005">
<DESCRIPTION>
<P>BTX-A funded by Allergan.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-02-10 08:23:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Grise-2008">
<DESCRIPTION>
<P>No conflicts of interest declared; "No funding or grant".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-03 14:18:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Herschorn-2009">
<DESCRIPTION>
<P>"investigator initiated clinical trial funded by Allergan".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:04:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karsenty-2005">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-21 09:38:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-King-2007">
<DESCRIPTION>
<P>Funding by Allergan.</P>
<P>"industry funding only investigator initiated and executed study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-21 09:55:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuo-2006">
<DESCRIPTION>
<P>Some of the BTX supplied by Allergan.</P>
<P>"ACKNOWLEDGMENT. To Allergan, Incorporated, Irvine, California for providing part of the botulinum A toxin."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:11:54 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kuo-2007">
<DESCRIPTION>
<P>Medications provided by Allergan.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:13:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lucioni-2008">
<DESCRIPTION>
<P>Research grant from Allergan.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:14:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2009">
<DESCRIPTION>
<P>No funding declared.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:18:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sahai-2005">
<DESCRIPTION>
<P>3 authors have financial or other relationships with Allergan.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:21:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schurch-2005">
<DESCRIPTION>
<P>1 author worked for Allergan, 2 had consultant agreement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:22:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Thavaseelan-2005">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-15 07:24:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Truzzi-2004">
<DESCRIPTION>
<P>Unclear.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-11-08 14:05:47 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-11-08 14:05:47 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Intravesical BTX-A vs Placebo</NAME>
<CONT_OUTCOME CHI2="2.1998147442925475" CI_END="109.8051658318757" CI_START="30.62770531019693" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="70.21643557103631" ESTIMABLE="YES" I2="54.54162662585497" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2011-10-06 23:17:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.138027408873445" P_Q="1.0" P_Z="5.084128566616483E-4" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="28" UNITS="ml" WEIGHT="100.0" Z="3.4762843853605925">
<NAME>Change in PVR at 4-6 weeks</NAME>
<GROUP_LABEL_1>Botulinum Toxin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours botulinum toxin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="162.4776192348616" CI_START="44.3223807651384" EFFECT_SIZE="103.4" ESTIMABLE="YES" MEAN_1="98.0" MEAN_2="-5.4" MODIFIED="2010-11-07 09:56:38 +0000" MODIFIED_BY="[Empty name]" ORDER="29" SD_1="67.4" SD_2="67.4" SE="30.142196336697168" STUDY_ID="STD-Finney-2006" TOTAL_1="10" TOTAL_2="10" WEIGHT="44.90525580447669"/>
<CONT_DATA CI_END="96.50551430238968" CI_START="-10.165514302389681" EFFECT_SIZE="43.17" ESTIMABLE="YES" MEAN_1="52.06" MEAN_2="8.89" MODIFIED="2010-11-07 09:56:52 +0000" MODIFIED_BY="[Empty name]" ORDER="30" SD_1="79.2" SD_2="79.2" SE="27.21249712907656" STUDY_ID="STD-Sahai-2005" TOTAL_1="16" TOTAL_2="18" WEIGHT="55.094744195523305"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.225944023117357" CI_END="-3.0304408104890497" CI_START="-5.902333101012375" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.466386955750712" ESTIMABLE="YES" I2="35.75271500759201" I2_Q="75.88677301138469" ID="CMP-001.02" MODIFIED="2011-11-08 14:04:35 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1828982989892044" P_Q="0.04170597607602555" P_Z="1.0855204148318212E-9" Q="4.147101507700048" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="77" TOTAL_2="73" UNITS="" WEIGHT="200.0" Z="6.096299365527888">
<NAME>Change in Urinary Frequency</NAME>
<GROUP_LABEL_1>Botulinum Toxin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours botulinum toxin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.4121336254587612" CI_END="-4.071794173475112" CI_START="-8.921860896403915" DF="2" EFFECT_SIZE="-6.496827534939514" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" MODIFIED="2010-11-07 10:00:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8137787928460538" P_Z="1.5137806957915053E-7" STUDIES="3" TAU2="0.0" TOTAL_1="51" TOTAL_2="45" WEIGHT="100.0" Z="5.250875383652537">
<NAME>4-6 weeks</NAME>
<CONT_DATA CI_END="0.3417563038166307" CI_START="-11.14175630381663" EFFECT_SIZE="-5.3999999999999995" ESTIMABLE="YES" MEAN_1="-12.2" MEAN_2="-6.8" MODIFIED="2010-11-07 10:00:27 +0000" MODIFIED_BY="[Empty name]" ORDER="31" SD_1="6.4" SD_2="6.4" SE="2.929521332589206" STUDY_ID="STD-Flynn-2009" TOTAL_1="15" TOTAL_2="7" WEIGHT="17.837990302081597"/>
<CONT_DATA CI_END="-0.9694903574995761" CI_START="-16.030509642500423" EFFECT_SIZE="-8.5" ESTIMABLE="YES" MEAN_1="-22.5" MEAN_2="-14.0" MODIFIED="2010-11-07 10:00:30 +0000" MODIFIED_BY="[Empty name]" ORDER="32" SD_1="12.15" SD_2="12.15" SE="3.842167357104581" STUDY_ID="STD-Ghei-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="10.37018961396017"/>
<CONT_DATA CI_END="-3.6179301037227756" CI_START="-9.342069896277224" EFFECT_SIZE="-6.4799999999999995" ESTIMABLE="YES" MEAN_1="-7.51" MEAN_2="-1.03" MODIFIED="2010-11-07 10:00:35 +0000" MODIFIED_BY="[Empty name]" ORDER="33" SD_1="4.25" SD_2="4.25" SE="1.460266575739588" STUDY_ID="STD-Sahai-2005" TOTAL_1="16" TOTAL_2="18" WEIGHT="71.79182008395824"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6667088899585463" CI_END="-1.588147441823928" CI_START="-5.15200077526424" DF="1" EFFECT_SIZE="-3.3700741085440837" ESTIMABLE="YES" I2="40.00152000000002" ID="CMP-001.02.02" MODIFIED="2010-11-07 10:02:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1967000056635494" P_Z="2.099047452783622E-4" STUDIES="2" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.00000000000001" Z="3.706787715419861">
<NAME>12 weeks</NAME>
<CONT_DATA CI_END="-0.37622409937007806" CI_START="-4.7237759006299225" EFFECT_SIZE="-2.5500000000000003" ESTIMABLE="YES" MEAN_1="-2.18" MEAN_2="0.37" MODIFIED="2010-11-07 10:02:39 +0000" MODIFIED_BY="[Empty name]" ORDER="34" SD_1="2.48" SD_2="2.48" SE="1.1090897168398957" STUDY_ID="STD-Finney-2006" TOTAL_1="10" TOTAL_2="10" WEIGHT="67.19703565823669"/>
<CONT_DATA CI_END="-1.938761665693936" CI_START="-8.161238334306066" EFFECT_SIZE="-5.050000000000001" ESTIMABLE="YES" MEAN_1="-6.19" MEAN_2="-1.14" MODIFIED="2010-11-07 10:02:43 +0000" MODIFIED_BY="[Empty name]" ORDER="35" SD_1="4.62" SD_2="4.62" SE="1.5873956658627992" STUDY_ID="STD-Sahai-2005" TOTAL_1="16" TOTAL_2="18" WEIGHT="32.80296434176333"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.9398973075508" CI_END="-1.1536222860072103" CI_START="-2.244869161699923" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.6992457238535665" ESTIMABLE="YES" I2="27.952824394679993" I2_Q="35.22602843498291" ID="CMP-001.03" MODIFIED="2011-11-08 14:05:47 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.22514881009724652" P_Q="0.2140490842901298" P_Z="1.0347601452563346E-9" Q="1.543829991953244" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="105" TOTAL_2="102" UNITS="" WEIGHT="200.0" Z="6.103954098420749">
<NAME>Change in Incontinence Episodes</NAME>
<GROUP_LABEL_1>Botulinum Toxin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours botulinum toxin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.383044541395076" CI_END="-1.0096442130845638" CI_START="-2.1593647470723782" DF="3" EFFECT_SIZE="-1.5845044800784711" ESTIMABLE="YES" I2="44.269456124126435" ID="CMP-001.03.01" MODIFIED="2010-11-07 10:08:22 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.14580369054174347" P_Z="6.578918234803725E-8" STUDIES="4" TAU2="0.0" TOTAL_1="79" TOTAL_2="74" WEIGHT="100.0" Z="5.402307121582786">
<NAME>4-6 weeks</NAME>
<CONT_DATA CI_END="-0.8803236863836625" CI_START="-6.1196763136163375" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="-3.1" MEAN_2="0.4" MODIFIED="2010-11-07 10:07:24 +0000" MODIFIED_BY="[Empty name]" ORDER="36" SD_1="2.92" SD_2="2.92" SE="1.3365941079938253" STUDY_ID="STD-Flynn-2009" TOTAL_1="15" TOTAL_2="7" WEIGHT="4.815366175493687"/>
<CONT_DATA CI_END="-0.546819315434119" CI_START="-1.873180684565881" EFFECT_SIZE="-1.21" ESTIMABLE="YES" MEAN_1="-2.42" MEAN_2="-1.21" MODIFIED="2010-11-07 10:07:42 +0000" MODIFIED_BY="[Empty name]" ORDER="37" SD_1="1.07" SD_2="1.07" SE="0.3383637096380166" STUDY_ID="STD-Ghei-2005" TOTAL_1="20" TOTAL_2="20" WEIGHT="75.13821040656876"/>
<CONT_DATA CI_END="-1.0831177970383474" CI_START="-3.8768822029616525" EFFECT_SIZE="-2.48" ESTIMABLE="YES" MEAN_1="-1.75" MEAN_2="0.73" MODIFIED="2010-11-07 10:08:02 +0000" MODIFIED_BY="[Empty name]" ORDER="38" SD_1="2.69" SD_2="2.69" SE="0.7127080976895908" STUDY_ID="STD-Herschorn-2009" TOTAL_1="28" TOTAL_2="29" WEIGHT="16.935772691531334"/>
<CONT_DATA CI_END="0.46939254070159153" CI_START="-6.049392540701591" EFFECT_SIZE="-2.79" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-0.71" MODIFIED="2010-11-07 10:08:22 +0000" MODIFIED_BY="[Empty name]" ORDER="39" SD_1="4.84" SD_2="4.84" SE="1.6629859356657897" STUDY_ID="STD-Sahai-2005" TOTAL_1="16" TOTAL_2="18" WEIGHT="3.1106507264062055"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.013022774202481572" CI_END="-1.009015226937699" CI_START="-4.474926160946161" DF="1" EFFECT_SIZE="-2.74197069394193" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" MODIFIED="2010-11-07 10:08:56 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9091447545799834" P_Z="0.0019276724596870869" STUDIES="2" TAU2="0.0" TOTAL_1="26" TOTAL_2="28" WEIGHT="100.0" Z="3.1011551705254305">
<NAME>12 weeks</NAME>
<CONT_DATA CI_END="1.5020036866522757" CI_START="-6.562003686652274" EFFECT_SIZE="-2.5299999999999994" ESTIMABLE="YES" MEAN_1="-4.27" MEAN_2="-1.74" MODIFIED="2010-11-07 10:08:36 +0000" MODIFIED_BY="[Empty name]" ORDER="40" SD_1="4.6" SD_2="4.6" SE="2.057182539299806" STUDY_ID="STD-Finney-2006" TOTAL_1="10" TOTAL_2="10" WEIGHT="18.472810022334734"/>
<CONT_DATA CI_END="-0.8707295989670378" CI_START="-4.7092704010329625" EFFECT_SIZE="-2.79" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-0.71" MODIFIED="2010-11-07 10:08:56 +0000" MODIFIED_BY="[Empty name]" ORDER="41" SD_1="2.85" SD_2="2.85" SE="0.9792375860841944" STUDY_ID="STD-Sahai-2005" TOTAL_1="16" TOTAL_2="18" WEIGHT="81.52718997766526"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-11-08 14:05:48 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2011-10-29 14:36:30 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>PRISMA Study flow diagram - the flow of literature through the searching process. For details of why records were excluded please see the Characteristics of Excluded Studies table</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2011-11-08 14:04:36 +0000" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Intravesical BTX-A vs Placebo, Outcome: 1.2 Change in Frequency.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2011-11-08 14:05:48 +0000" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Intravesical BTX-A vs Placebo, Outcome: 1.3 Change in Incontinence Episodes.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2011-10-06 23:17:35 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_MORE_DECIMALS:NO;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Intravesical BTX-A vs Placebo, Outcome: 1.1 Change in PVR at 4-6 weeks.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;48 reports of 19 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;48 reports of 19 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 reports of 8 included studies&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Original search: 19 records identified from Specialised Register&lt;/p&gt;" WIDTH="120">
<OUT TEXT="&lt;p&gt;11 records excluded&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;40 reports: 20 reports of 11 new trials and 20 extra reports of 4 of the 8 already included trials&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;Updated search 2009/2010: 51 records identified from Specialised Register&lt;/p&gt;" WIDTH="120">
<OUT TEXT="&lt;p&gt;11 records excluded&lt;/p&gt;"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>